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1.1 THYMUS 
 
In mammals and man, the thymus is the primary lymphoid organ for 
T lymphocyte maturation, whereas the bone marrow serves as the 
primary lymphoid organ for the B lymphocyte compartment, although the 
gut-associated lymphoid tissue is its phylogenetic ancestor.  
The thymus is the first of the lymphoid organs to be formed in all 
vertebrates, and grows considerably immediately after birth in response to 
postnatal antigen stimulation and the demand for large numbers of mature 
T cells. Genetic factors also influence the age of onset, rate and 
magnitude of thymus dependant immunological function. The thymus 
reaches maximal size by sexual maturity and then gradually involutes [1].  
In humans, the thymus is located in the mediastinum, just anterior to 
the ascending aorta and inferior to the left brachiocephalic vein. If 
examined when its growth is most active, it consists of two lateral lobes 
placed in close contact along the middle line, situated partly in the thorax, 
partly in the neck, and extending from the fourth costal cartilage upward, 
as high as the lower border of the thyroid gland. It is covered by the 
sternum, and by the origins of the Sternohyoidei and Sternothyreoidei 
muscles. Below, it rests upon the pericardium, being separated from the 
aortic arch and great vessels by a layer of the middle cervical fascia. In 
the neck it lies on the front and sides of the trachea, behind the 
Sternohyoidei and Sternothyreoidei muscles.  
The thymus is of a pinkish-gray color, soft, and lobulated on its 
surfaces. This superficial arrangement corresponds to a three-
dimensional (3D) organization of its parenchyma, specifically  to 3D 
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prismatic structures, hystologically constituted by two subcompartments, 
the cortex and the medulla. Each compartment contains distinct 
populations of thymic ephitelial cells (TEC), as weel as mesenchymal 
cells, endothelial cells and dendritic cells.  
 
 
Fig. 1 A: Structure of the mammals thymus. The thymus is a lympho-ephitelial organ surrounded by a connective 
capsule. Each of its constituting units , the thymic lobule can be divided into a central medulla (m) region, which contains 
medullary thymic ephitelial cells (m TECs), and an outer cprtex (c), which contains cortical thymic ephitelial cells (c TECs). B: 
Histology of the adult mouse thymus. Hematoxylin and eosin-stained sagittal section highlighting the thymus subcompartments. 
 
 
The thymus provides a unique microenvironment for the efficient 
production of a diverse T cell repertoire[2]. However, after puberty it 
begins to regress. This involution , which seems to occur in almost all 
vertebrates, rodents included, suggesting that this is an evolutionary 
ancient and conserved process. Age-associated thymic involution 
includes a decrease in tissue mass and cellularity, together with a loss of 
tissue organization, leading to a reduction in the cell output. This decline 
in the T cell output is believed to have a major impact on the properties of 
the peripheral T cell pool such that with increasing age, these cells exhibit 
alterations in phenotype and function, loss of diversity, and replicative 
senescence[3]. 
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1.1.1 Anatomy of the thymus 
 
In mammals and man, the thymus has a bilobed structure, it is 
classidfied as a lympho-ephitelial organ containing many developing 
lymphocytes, and is surrounded by a capsule of connective tissue. The 
two lobes generally differ in size; they are occasionally united, so as to 
form a single mass; sometimes they are separated by an intermediate 
lobe. Each lateral lobe is composed of numerous lobules, featured as 3D 
prismatic structures of prismatic geometry, held together by delicate 
areolar, stromal tissue; the entire gland being enclosed in an investing 
capsule of a similar but denser structure. The lobules vary in size and 
consists of a cortical and a medullary portion. The cortical portion is 
mainly composed of lymphoid cells, supported by a network of finely 
branched cells, the cortical thymic ephitelial cells (cTECs), which is 
continuous with a similar network in the medullary portion, formed by 
medullary TEC (mTECs).  A network of reticular TECs forms an adventitia 
around   the blood vessels. In the medullary portion, this reticulum is 
coarser than in the cortex, the lymphoid cells are relatively fewer in 
number, and there are found peculiar nest-like bodies, the concentric 
corpuscles of Hassall, originating from involution of local TECs appoases 
in concentric layers. These concentric corpuscles are characterized by a 
central mass, consisting of one or more granular elelments, and of a 
capsule which is formed of epithelioid cells.  
Each lobule is surrounded by a vascular plexus, from which vessels 
pass into the interior, and radiate from the periphery toward the center, 
forming a second zone just within the margin of the medullary portion. In 
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the center of the medullary portion there are very few vessels, and they 
are of minute size. 
Arteries supplying the thymus are derived from the internal 
mammary, and from the superior and inferior thyroids. The veins end in 
the left innominate vein, and in the thyroid veins. The nerves are 
exceedingly minute; they are derived from the vagus and sympathetic 
chain. Branches from the descendens hypoglossus and phrenic nerves 
reach the investing capsule, but do not penetrate into the substance of the 
gland. The thymic arteries follow the course of the interlobular connective 
tissue septae, and enter the thymic parenchyma at the corticomedullary 
junction. The corticomedullary arterioles ramify into capillaries that extend 
into the cortex and medulla. In the cortex they form a complex of capillary 
arcades which together with perivascular lymphocytes, macrophages and 
peripheral reticular epithelial cells form the blood-thymus barrier[4]. 
Capillaries in the cortex are rarely fenestrated[5]. This restricts access of 
circulating antigenic molecules to developing cortical lymphocytes. By 
contrast, medullary capillaries are fenestrated and freely permeable to 
circulating antigens. Blood drains into the postcapillary venules, and finally 
returns to the corticomedullary junction in medullary veins [4]. 
Prothymocytes are thought to enter the thymic stroma through the 
large venules at the corticomedullary junction, and re-enter the circulation 
through the vascular lining of post-capilliary venules. These perivascular 
areas contain accumulations of phenotypically mature T cells that express 
the marker Mel 14, a receptor involved in the migration of lymphocytes 
through the lymphoid vasculature [6]. Efferent lymphatics drain into an 
adjacent pair of lymphnodes. The thymus has no afferent lymphatics. The 
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rodent thymus has an abundant noradrenergic innervation but some 
cholinergic innervation has also been demonstrated [7]. Nerves follow the 
vasculature, within the capsule and septae and the highest concentration 
of nerve fibres is in the corticomedullary junction.  
 
 
Fig. 2 Schematic diagram outlining the pathway of T cell development. Aging can impact on variety of pathways during 
the development of T cells.  
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1.1.2 Development of the thymus 
 
The epithelium of the thymus is derived from the embryonic 
endodermal layer, with possible contributions from the ectoderm, through 
a series of differentiating steps, each of which must be completed in order 
to provide the optimum environment for thymic development and function. 
The roof of the endodermal yolk sac is folded into the expanding embryo 
as the foregut (Fig.3 ). The embryonic pharynx is quite important for the 
development of many organs, including the thyroid and parathyroid glands 
as well as the thymus.  
 
Fig.3  Representation of the foregut formation in the embryo development. 
 
Alongside the thymocites, at different stages of maturation, the 
thymic environment is formed by ephitelial cells, which form a meshwork 
to provide mechanical support and stimuli for the proliferation and 
development of thymocites and by macrophages, dendritic cells, fibroblast 
and matrix molecules[8].  
The developing pharyngeal region in contact with the ectodermal 
layer produces inclusions of ectodermal cells into the thymus, a 
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mechanism possibly explaining the heterogeneity of ephitelial cells in yhe 
mature thymus. The mass of endodermal cells from the 3rd and 4th 
faringeal pouch give rise to the primordial thymus (and forthcoming 
parathyroid glands), and attracts lymphoid precursor cells that are brought 
to this region through the bloodstream. The lymphoid precursor cells leave 
the blood vessels and migrate through the mesenchyme into the primitive 
organ bud. This migration starts between 11 and 12 gestation days (GD) 
[9]. In the rat, the process is less well known and according to the few 
existing reports, it starts between GD 13 and 15[10]. The earliest phase of 
organogenesis, culminates in the formation of two primordial buds, one of 
each antimeres, surrounded by a condensing mesenchymal capsule. By 
GD 13.5 for mice and 16.5 for rats the parathyroid and thymus are 
separated into physically distinct organs and soon afterwards they reach 
their approximate adult positions within the embryo (Fig.4 ).  
 
Fig. 4 Photomicrograph showing sagittal sections of the rat embryo. A at 10 GD the thymus is not presetn; B at 14 GD it 
is visible at rudiment of the organ and C at 19 GD the two lobes can be distinguished. Hematoxylin-eosin staining. 
 
In the embryonic thymic cortex, rat lymphocytes, in cortex, show a 
different antigenic pattern at the 16th day and at the 31th day after the 
birth. In adult rats, differences in CD4:CD8 cell ratio involve the major 
histocompatibility complex (MHC) haplotype[11], and peripheral CD4+ T 
cells predominate over CD8+ T cells but the origin of these differences 
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has not yet been elucidated.  
Unlike adult thymic precursors, fetal thymic progenitors give rise to 
reduced numbers of CD4+ peripheral T cells in chimeric animals 
(CD4:CD8 cell ratio <1). This relative under- representation of CD4+ 
peripheral T cells was seen 4–16 weeks after either intrathymic injection 
of suspensions of foetal CD4-CD8- thymocytes into adult thymuses, or 
transplantation of foetal thymic lobes under the kidney capsule of adult 
host rats. Then, foetal thymic precursors seem to be responsible for a 
relative underproduction of CD4+ peripheral T cells, regardless of the 
developmental age of the thymic stromal environment. However, the 
developmental age of the thymic stromal environment is the key 
regulatory element involved in the generation of distinct proportions of 
CD4+ and CD8+ thymocytes.  
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1.1.3 Thymic epithelial and dendritic cells in the adult 
thymus 
 
The bulk of the supporting framework in the thymus is composed of 
a network of TECs [12]. In the subcapsular region of the thymus, TECs 
form a layer, 1 or 2 cells deep. In the outer cortex, TECs are thin and 
sheet like, but elsewhere they assume a stellate appearance.  
TECs manifest expression of MHC class I antigens, neuropeptides, 
neurophysin, oxitocin/vasopressin and neuroendocrine markers. They are 
responsible for interleukins IL-6 and IL-7 secretion, and for secretion of 
thymic hormones. Superficial TECs demonstrate common phenotype 
traits with medullary traits [13]. TECs in the mid and deep cortex also 
have slender cytoplasmic processes providing a large surface area for 
cell–cell interactions with developing thymocytes[14].  
Morphologically, TECs are characterized by electronlucent vacuoles 
with a small amount of moderate electrondense material, linked to 
secretory activity. The cortical TECs are distinguished by expression of 
both MHC class I and II molecules and protein gene product 9.5 (PGP 
9.5). This latter is also a marker of a specific population of cortical TECs, 
known as thymic nurse cells (TNCs) [13]. 
In the outer cortex, some TECs appear to completely surround and 
enclose a large number (about 10–250) of thymocytes[15]. Moreover, 
TECs have been described in the subcapsular and outer cortical regions 
of the human [16] and rat thymus[17].  
In contrast to cortical TECs, those contain a small number of 
thymocytes [18]. Scanning electron microscopic images of the mouse 
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thymus have suggested that thymocytes migrate in or out these lympho-
stromal complexes[17]. TECs are thought to provide a specialized 
microenvironment for T-cell differentiation[19]. Although the epithelium 
they constitute is thought to be a sessile component of the thymus[20], 
the subcapsular epithelium in particular may be a dynamic structure, since 
transitional forms have been observed between sheet-like TECs, basket-
like TECs, and TECs depending on the type of cortical lympho- stromal 
interaction.  
Most medullary TECs are closely packed displaying voluminous 
cytoplasm and short processes. They are commonly subdivided into two 
subsets, representing different stages of their differentiation[21,13].Cells 
of the first subset are defined ‘‘undifferentiated’’ and are around 1% of the 
total medullary population. They remain unrelatively unknown and are 
identified on the basis of ultrastructural traits in the outer medulla, as 
solitary cells or arranged in small groups of cells, which comprise forms of 
traits intermediate with those of the second subsubset of medullary TECs. 
The second type of TECs are polygonal, with a rich cytoplasm, polarized 
with respect to the position of organelles and having ultrastructural traits 
of endocrine cells. They express a wide range of peptide hormones and 
several co-stimulatory molecules including CD40.  
In the adult mouse, dendritic cells are present mainly in the medulla; 
they are voluminous with electronlucent cytoplasm penetrating between 
surrounding lymphoid cells (Fig.5).  
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Fig.5 Electron micrograph showing thymic morphology in the rat. Dendritic cells are characterized by electron-lucent 
cytoplasm. 
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1.1.4 Composition of the thymus microenvironment 
The thymus microenvironment forms a complex network of 
interaction that comprises non lymphoid cells, extracellular matrix 
elements (ECM), matrix metalloproteinases, cytokines, chemokines, and 
other soluble proteins. During their journey inside the thymus, thymocites 
interact with stromal cells and extracellular matrix proteins to receive 
appropriate signals for survival, proliferation and differentiation. 
On day 13 of fetal lifea number of ECM components have been 
observed in the thymus. Collagen type I expression was restricted to a 
few cells in the capsule area, whereas laminin was present in the capsule 
and in some scattered stromal cell clusters. In contrast, a filamentous 
network observed throughout  the organ shows positivity for Collagen type 
IV and fibronectin[25].  
On day 15 of fetal life it is not possible to distinguish cortical and 
medullary regions by ECM expression patterns, and the entire organ 
displayed a thin network of laminin, fibronectin and collagen type IV. On 
day 17 a similar profile is apparent, although all these proteins were 
additionally detected at basement membranes and intralobular 
perivascular spaces. At this stage collagen type I expression is similar to 
that found in young adult animals. The complete adult pattern of thymic 
ECM distribution was achieved on day 19 of fetal life[25]. 
The distribution of ECM in the normal thymus does not follow a 
homogeneus pattern, and glycoproteins such as fibronectin, laminin and 
collagen type IV are not restrictly located at typical basement membrane 
sites. In the medullary region of the thymic lobules, they form a rather 
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thick medullary network, whereas very thin ECM fibres are found within 
the cortex.  
 
Fig.6  Intrathymic distribution of fibronectin in human thymus, as revealed by confocal mycroscopy. The fibronectin-
containing network is denser in the medulla (right part on the panel) if the thymic lobule, as compared to the cortex (left part of the 
panel). Additonally, Fibronectin is seen around vessels. 
 
The distribution of collagen type I is limited to the capsule, 
intraseptal and perivascular spaces[22]. 
The fibronectin is located throughtout the all thymic parenchima and 
outlines the cortico-medullary junction of the thymic lobules[23]. Different 
isoform of the laminin could be found into the thymus. Laminin 2 is 
restricted to cortical ephitelial cells  whereas laminin 5 is located 
surrounding small blood vessels[24]. Laminin 1 and 2 can modulate 
thymocyte migration within TNCs complexs. In the human thymus a large 
number of fibers in the interior of the connective tissue septae are made 
of collagen type I whereas only some fibers are labelled with collagen type 
IV. Instead the basement membrane bordering these septae contained 
large amount of collagen type IV. The interior of interlobular septae 
cointain laminin and fibronectin; in contrast the connective fibres situated 
at the corticomedullary junction are made up of  collagen type IV, type I 
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and fibronectin. 
 
 
 
Fig.7 Frozen  section of adult mouse thymus showing the distribution pattern of a collagen type I, b type III and C type 
IV and D fibronectin. A part of cortex (C) of a thymic lobule , as well as septum containing a blodd vessel(V) coul be seen. Bar 
50µm  
 
The extracellular localization of the laminin is mainly medullary and 
also medullary TECs contain and produce this ECM protein. 
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Fig.8 Frozen  section of adult mouse thymus showing the distribution pattern of fibronectin within the thymic lobules. (B) 
Higher magnification of the fibronectin-positive network occurring in the medullary region. Bars: a- 50µm b-20µm 
 
In the mouse fibronectin and laminin are strongly detected at the 
basement membranes, not only in the connective tissue septa but also in 
the interlobular perivascular spaces. In addition, filaments containing 
fibronectin, laminin and few collagen type IV have been found within the 
thymic medulla. 
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 Fig.9 Frozen  section of adult mouse thymus showing the distribution pattern of fibronectin within the thymic lobules. 
(B) Higher magnification of the fibronectin-positive network occurring in the medullary region. Bars: a- 50µm b-20µm 
 
In normal young adult animals , the distribution patterns of both 
interstitial and basement membrane proteins were similar to those 
previously described for the infant human thymus[22].  
 
 
Fig. 10 Extracellular matrix labelling in the fetal thymus. a) fibronectin and b) laminin labeling patterns in a 13- day fetal 
thymus. c) the fibronectin network observed in a 15.day fetal thymus. Bar-20µm 
 
All ECM components are produced by thymic microenvironmental 
cells, which also drive thymocyte differentiation. Signals triggered by ECM 
are conveyed into thymocytes or microenvironmental cells through 
specific membrane receptors, and most of them belong to the type, such 
    
 
 
24
as the VLA-3, VLA-4, VLA-5 and VLA-6. In vitro studies revealed that 
adhesion of thymocytes to thymic integrin microenvironmental cells is 
mediated by extracellular matrix. Such an adhesion is preferentially done 
by immature thymocytes[26]. 
Cultured TECs produce laminin, fibronectin and type IV collagen, 
fibroblasts and major histocompatibility complex (MHC) class II+ 
phagocytic cells of the thymic reticulum also produce these ECM 
components[27,28,29].  
Fibronectin, recognized by VLA-5 (very late antigen-5) through its 
RGD motif, is located throughout the thymic parenchyma, whereas the 
isoform derived from alternative splicing of fibronectin mRNA (being 
recognized by VLA-4 through the LEDV motif) seems to be restricted to 
the medulla[30]. 
In addition, there are some isoforms of laminin. Laminin-5, formed 
from the α3β3γ2 heterotrimer, was detected also in the human thymus, 
being produced by medullary TECs and able to trigger outside-in signals 
to thymocytes[31].In the mouse system, anti-laminin-5 monoclonal 
antibodies significantly blocked thymocyte expansion, as well as double 
negative(DN) → double positive (DP) differentiation[32].  
In the human thymus, laminin-1 seems to be distributed widely 
within lobules and septae, whereas laminin-2 is restricted to cortical 
TECs.  
Laminin-1 and laminin-2 can modulate thymocyte migration within 
TNC complexes and in addition to the DN → DP progression, the 
migration of DP thymocytes is also influenced by laminin(s).  
Cells of the thymic microenvironment express fibronectin receptor 
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(VLA-4 and VLA-5), as well as laminin receptors (VLA-3 and VLA-6) [33]. 
These receptors are also expressed by differentiating thymocytes. ECM 
proteins form molecular bridges between thymocytes and 
microenvironmental cells, a biological event that potentially provides 
signals to both cell types.  
Thymocyte adhesion to cultured TECs is enhanced in the presence 
of ECM components, such as fibronectin and/or laminin, whereas 
antibodies against these adhesive molecules promote an opposite effect.  
Thymocyte release from TNCs is enhanced by fibronectin and 
laminin and diminished by corresponding anti-ECM or anti-ECM receptor 
antibodies. 
ECM-mediated epithelial–thymocyte interactions play a role in the 
traffic of thymocytes within TNCs, affecting both the entrance and exit of 
lymphocytes in this particular microenvironmental niche.  
The expression of thymic ECM molecules in aging  normal mice (50 
week-old) is more intense than that observed in young animals. 
In addition to a higher expression of basement membrane 
components in the medullary region, there is a formation of a cortical 
network of fibronectin, laminin and collagen type IV.  
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1.1.5 Physiological function of the Thymus 
 
The thymus supports the differentiation and selection of T cells. The 
thymic development of T cells consists of several processes that require 
the dynamic relocation of developing lymphocytes into, within and out of 
the multiple environments of the thymus trought distinct cell-cell and cell-
matrix interactions. These processes include:1) the entry of lymphoid 
progenitor cells into the thymus; 2) the generation of CD4+CD8+ double-
positive (DP) thymocytes at the outer cortex of the thymus;3) the positive 
and negative selection of DP thymocytes in the cortex; fourth, the 
interaction of positively selected thymocytes with medullary thymic 
epithelial cells (mTECs) to complete thymocyte development and ensure 
central tolerance; 4) the export of mature T cells from the thymus [34-39] 
(FIG.11).  
Chemokines might act in concert with extracellular matrix (ECM), 
resulting in the migration of a given cell subset, either within the thymus or 
at the entrance into and/or exit from the organ [40].  
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Fig. 11 Traffic of thymocytes for T-cell development and selection. a | In the postnatal thymus, circulating T-
lymphoid progenitor cells migrate into the thymic parenchyma through the vasculatures that are enriched around the cortico– 
medullary junction. b | The outward migration of CD4–CD8– double-negative (DN) thymocytes to the capsule is regulated by 
chemokine signals through CXC- chemokine receptor 4 (CXCR4) and CC-chemokine receptor 7 (CCR7). c | Further outward 
migration of the DN thymocytes to the subcapsular region is mediated by CCR9 signals. d | CD4+CD8+ double-positive (DP) 
thymocytes generated in the outer cortex are motile, interacting with stromal cells that are localized in the cortex for positive and 
negative selection. e | Positively selected DP thymocytes that gain the capability to survive and differentiate into CD4 or CD8 
single- positive (SP) thymocytes show an increase in the surface expression of CCR7, through which the cells are attracted to the 
medulla, which expresses CCR7 ligands. f | In the medulla, further selection of SP thymocytes includes the deletion of tissue-
specific-antigen-reactive T cells and the generation of regulatory T cells. g | Mature SP thymocytes express sphingosine-1-
phosphate receptor 1 (SP1)through which the cells are attracted back to the circulation that contains a high concentration of 
sphingosine-1-phosphate. cTEC, cortical thymic epithelial cell; DC, dendritic cell; mTEC, medullary thymic epithelial cell; PSGL1, 
platelet-selectin glycoprotein ligand 1.  
 
 
The seeding of the thymus with lymphoid progenitor cells occurs as 
early as embryonic day 11.5 (E11.5) in mice at the eight week of gestation 
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in humans [41-42], and is mediated by at least two different pathways: the 
vasculature-independent pathway, which probably occurs during the early 
stage of embryonic development before vascularization of the thymus, 
and the vasculature-dependent pathway, which probably occurs in the late 
stage of embryogenesis and postnatally after vascularization.  
It is thought that vasculature-independent colonization of the fetal 
thymus is regulated by the chemotactic attraction of lymphoid progenitor 
cells to the thymic primordium (FIG. 12a). The partial but significant roles 
of two chemokines, CC-chemokine ligand 21 (CCL21) and CCL25, in this 
early stage of fetal thymus colonization have been reported. CCL21 and 
CCL25 are expressed by the fetal thymus primordium, along with several 
other chemokines[43-44]. Ccl25 and Cxcl12 regulate the hematopoietic 
precursor homing process [45]and have also chemotactic functions.  
CCL21 and CCL25 are partially involved in fetal thymus 
colonization. CCL25 is expressed by TECs and dendritic cells and attracts 
immature thymocytes. The CC-chemokine receptor 9 (CCR9) receptor for 
CCL25 is expressed at various stages of murine thymocytes 
differentiation, particularly in DP and CD8+ single positive cells[40].  
Interestingly, the entry of lymphoid progenitor cells into the thymus is 
not a continuous event but an intermittent and gated event that occurs in 
waves during embryogenesis and in adulthood[46-48]. During 
embryogenesis, distinct waves of thymus-colonized cells give rise to 
distinct progenies of γδ T cells with different usages of T-cell receptor 
(TCR) -Vγ and Vδ chains, indicating that T-lymphoid progenitor cells that 
colonize the fetal thymus differ in developmental potential from T-
lymphoid progenitor cells that enter the postnatal thymus[48-52].  
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Following entry into the thymus, lymphoid progenitor cells begin their 
development into T cells through the developmental pathway that is 
commonly identified by the expression profiles of CD25 and CD44, until 
the developmental checkpoint at the CD4–CD8– CD25+CD44– (double-
negative 3, DN3) stage[53-54].  
Only the cells that succeed in in-frame rearrangement of the gene 
encoding the TCR β-chain are selected for further differentiation beyond 
this DN3 stage. The initial thymocyte development until the DN3 stage is 
promoted by Notch-mediated signals delivered by binding of Delta ligands 
[55-56]  and is supported by signals delivered by interleukin-7 (IL-7) [57-
58]: the signals derived from cortical thymic epithelial cells (cTECs) (FIG. 
12c). Along this developmental pathway, immature DN thymocytes 
promote the differentiation of thymic stromal cells and trigger the 
formation of the cortical-epithelial environment in the thymus[59-62].  
The differentiation of thymocytes from the DN1 stage to the DN3 
stage regulates the differentiation of TEC precursor cells into cTECs that 
form the cortical environment in the thymus (FIG. 12b).  
Concomitantly, DN thymocytes relocate outwards from the cortico–
medullary junction to the subcapsular region of the thymic cortex [63] 
(FIG. 11b). Several chemokine receptors, including CXCR4, CCR7 and 
CCR9, have been suggested to be involved in this movement of immature 
thymocytes[64-66].  
The chemokine-dependent outward localization of the thymus-
seeded progenitor cells from the cortico–medullary junction to the outer 
cortex seems to be essential for optimal initiation of thymocyte 
development, although the accumulation of DN3 thymocytes in the 
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subcapsular region might not be required for further thymocyte 
development.  
In the thymic cortex, on their way to the subcapsular region, DN 
thymocytes begin to rearrange their Tcrb locus and the cells that succeed 
in generating the in-frame Tcrb rearrangement begin assembling TCRβ 
and pre-TCRα (pTα) chains to form the cell-surface pre-TCR complex[67-
68]. The successful expression of the pre-TCR complex on the cell 
surface[68-69], along with the Delta–Notch interaction [70], initiates the 
signals for further development to DP thymocytes that express TCRαβ 
antigen receptors. This is the first checkpoint of  T-cell development at the 
DN3 stage which censors the cells that have succeeded in in-frame TCRβ 
rearrangement and allows further development of thymocytes beyond the 
DN3 stage. It has been shown that the subcapsular region is rich in 
transforming growth factor-β (TGFβ), which retards the cell-cycle 
progression of pre-DP thymocytes and negatively regulates the 
generation of DP thymocytes[71], indicating that the migration of pre-DP 
thymocytes to the subcapsular region might have a role in regulating the 
rate of production of DP thymocytes (FIG. 11c).  
DP thymocytes that are newly generated in the cortex express low 
levels of the TCRαβ antigen–receptor complex. The cortical DP-thymocyte 
population contains the unselected repertoire of T cells, making this 
population the main target of the most rigorous positive and negative 
selection[72-73].  
Most thymocytes in the cortex of the adult thymus are highly motile 
and they pause to interact through their TCR with peptide–MHC 
complexes that are expressed by stromal cells, such as cTECs, and 
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dendritic cells in the cortex[74]. Following TCR recognition of peptide–
MHC ligands at low-avidity interactions, DP thymocytes are induced to 
receive signals for survival and further differentia- tion into single-positive 
(SP) thymocytes.  
High-avidity interactions elicit signals that lead to the deletion of 
thymocytes. Apoptosis is the mechanism of negative selection. The 
process of negative selection contributes to the deletion of self-reactive T 
cells, thereby avoiding autoimmunity. In addition to the negatively selected 
thymocytes, most cortical DP thymocytes fail to receive TCR signals and 
are also destined to die at this stage. Therefore, only 3–5% of developing 
thymocytes survive this checkpoint of T-cell development at the cortical 
DP-thymocyte stage(FIG. 11d; FIG. 12d) [75-76].  
Positively selected DP thymocytes then begin relocating from the 
cortex to the medulla[77]. The expression of the chemokine receptor 
CCR7 by developing thymocytes is associated with the phenotypic stage 
of cortex-to-medulla migration during the development of immature DP 
thymocytes to mature SP thymocytes[78-79]. Following TCR ligation, 
cortical DP thymocytes show an increase in cell-surface expression of 
CCR7. By contrast, CCR7 ligands (CCL19 and CCL21) in the postnatal 
thymus are predominantly produced by mTECs[80]. Therefore, cortical 
DP thymocytes that have received TCR-mediated signals are attracted to 
the medulla through CCR7-mediated chemotaxis (FIGS 11e).  
However, the migration of developing thymocytes to the medulla 
cannot be solely mediated by the passive inward flow, present in the 
postnatal thymus from the capsular and subcapsular areas to the 
medullary area[81-82].  
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The positive selection of thymocytes is a prerequisite for both the 
formation of the medulla and the migration of positively selected 
thymocytes to the medulla (FIG. 12e).  
The signals of the nuclear factor-κB (NF-κB)-mediated signal 
pathway, occuring through lymphotoxin-β receptor, tumour-necrosis-
factor-receptor-associated factor 6 (TRAF6), NF-κB-inducing kinase (NIK) 
and the NF-κB subunit RelB are crucial for the development of the thymic 
medulla[83-86].  
Positively selected DP thymocytes are induced to differentiate into 
SP (that is, CD4+CD8– or CD4–CD8+) thymocytes and relocate to the 
medulla. The SP thymocytes are assumed to spend approximately 12 
days in the medulla before being exported from the thymus[87]. During 
this period, the SP thymocytes go through a maturation process that is 
commonly identified by the expression profiles of CD62 ligand (CD62L; 
also known as lymphocyte (L)-selectin) and CD69, and with the 
acquisition of functional capability of these cells as mature but naive T 
cells[88-90]. The newly generated SP thymocytes are CD62LlowCD69hi 
semi-mature cells that are func- tionally incompetent and susceptible to 
various apoptotic signals, including dexamethasone, and undergo further 
maturation to become mature SP thymocytes that are functional, 
dexamethasone-resistant and CD62LhiCD69low. The process of SP-
thymocyte maturation presumably occurs in the medulla and is 
accompanied by further deletion of self-reactive thymocytes that have 
escaped negative selection in the cortex (FIGS 11f). Such additional 
deletion in the medulla seems to be particularly important in establishing 
central tolerance to tissue- specific antigens, as mTECs express tissue-
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specific anti- gens promiscuously[91]. The expression of tissue-specific 
antigens by mTECs is at least partially dependent on the transcriptional 
factor autoimmune regulator (AIRE) [92-93]. 
 
 
FIG. 12 Crosstalk between thymocytes and thymic stromal cells. Thymic stromal cells, including the common 
progenitor thymic epithelial cells (pTECs), attract the entry of T-lymphoid progenitor cells to the thymus (signal a). The developing 
double-negative (DN) thymocytes are required for pTECs to generate cortical thymic epithelial cells (cTECs) (signal b) that form 
the cortical environment that is needed to promote the generation of double-positive (DP) thymocytes (signal c) and the positive 
selection of DP thymocytes (signal d). The generation of single-positive (SP) thymocytes by the positive selection of DP 
thymocytes is required for the development of mature medullary thymic epithelial cells (mTECs) (signal e) that form the medullary 
environment to support the maturation, further selection and export of mature SP thymocytes (signal f) to supply the peripheral T-
cell pool. Red arrows indicate crosstalk signals.  
 
This process of medullary tolerance is shown to occur, at least in 
part, through the deletion of self-reactive T cells[94-96]. 
The medulla is thought to be the place for the production of 
regulatory T cells[97-99]. It has been shown that most forkhead box P3 
(FOXP3)- expressing regulatory T cells within the thymus are found in the 
medulla[98]. Therefore, the period of maturation in the medulla seems to 
be essential for SP thymocytes to establish central tolerance by ensuring 
the deletion of T cells that are reactive to tissue-specific antigens and by 
producing regulatory T cells (FIGS 12f ).  
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Hassall’s corpuscles express TSLP, which activates thymic den- 
dritic cells that in turn induce the generation of regulatory T cells[100]. 
Independent studies have indicated that CCL17 is expressed by dendritic 
cells that are mostly localized in the medulla[100-101], and CCL22 is 
expressed by the outer walls of Hassall’s corpuscles[102-103], whereas 
CCR4 (a receptor for CCL22 and CCL17) is expressed by semi- mature 
SP thymocytes[79,102,103]. These chemokine signals might direct 
medullary semi-mature SP thymocytes to Hassall’s corpuscles and have a 
role in establishing central tolerance by enhancing the generation of 
regulatory T cells and/or optimizing negative selection. 
In the postnatal thymus, lymphoid progenitor cells that have just 
entered the thymic parenchyma are found mainly in the area close to the 
cortico–medullary junction, where the vasculature is well developed, 
indicating that the lymphoid progenitor cells enter the postnatal thymus by 
transmigrating from the blood to the thymic parenchyma, mainly through 
the area around the cortico–medullary junction (FIG. 11a) [63].  
Thymus seeding of the adult thymus is regulated by the adhesive 
interaction between platelet (P)-selectin glycoprotein ligand 1 (PSGL1), 
which is expressed by circulating lymphoid progenitor cells, and P-
selectin, which is expressed by the thymic endothelium[104]. Thymocyte 
emigration is an active process controlled by signals mediated by G-
protein-coupled receptors [105] phingosine-1-phosphate receptor 1 (of the 
S1P receptors, is expressed by mature SP thymocytes and that S1P
 
is 
required for the egress of T cells from the adult thymus[106]. During 
maturation from DP thymocytes, SP thymocytes acquire the expression of 
S1P [106-107]. 
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The chemoattraction of mature thymocytes to circulating S1P 
regulates the exit of mature T cells from the postnatal thymus(FIG. 11g). 
CCL19-mediated CCR7 signals contribute to thymocyte emigration in 
newborn mice but not in adult mice[108], indicating that there might be a 
developmental switch between CCR7-mediated emigration and S1P-
mediated emigration during ontogeny. The repulsive movement of SP 
thymocytes repelled from a high con- centration of CXCL12 has a role in 
the emigration of T cells from artificial thymus organoids[109].  
The export of mature thymocytes from the thymic parenchyma to the 
circulation is thought to occur through the perivascular space, which is 
channelled to post-capillary venules, arterioles and lymphatics[110-111].  
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1.2 The Natural  Scaffold: the extracellular matrix 
 
End-stage organ failure is a key challenge for the medical 
community because of the ageing population and the severe shortage of 
suitable donor organs available. It is a serious, growing, and costly issue. 
Every year in the USA alone, 120 000 people die from chronic lung 
disease[112], 112 000 die from kidney failure[113], 27 000 die from end-
stage liver disease[114], and 425 000 die from coronary heart 
disease[115]. Equally, injuries to or congenital absence of complex 
tissues such as the trachea, oesophagus, or skeletal muscle have few 
therapeutic options.  
At present, definitive treatment for end-stage organ failure is 
allogeneic transplantation. It is a well-established procedure but is a victim 
of its own success in that there is a growing disparity in numbers between 
the donor organ pool available for transplantation and the patients eligible 
for such a procedure, with high mortality rate in those who are on the 
waiting list[116]. 
 Patients fortunate enough to receive a donor organ endure life-long 
immunosuppressive therapy with its associated morbidity and also are at 
risk of acute or chronic organ rejection[117]. 
Recent advances in tissue engineering, an interdisciplinary field that 
applies the principles of engineering and life sciences toward the 
development of functional replacement tissue for clinical use, and 
regenerative medicine have established a foundation on which the 
functional replacement of whole organs and complex tissues such as 
skeletal muscle, trachea, and oesophagus seems possible. Many 
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developments employ the seeding and cultivation of cells onto acellular 
scaffolds[116]. These scaffolds can act as an inductive template for 
functional tissue and organ reconstruction after recellularisation with 
autologous stem cells or differentiated cells. This approach involves the 
use of naturally occurring extracellular matrix, obtained by the 
decellularisation of allogeneic or xenogeneic whole organs or tissues 
(Figure 13). The ready availability of an off-the-shelf xenogeneic scaffold 
that could subsequently be recellularised with autologous cells is a 
potential solution to the donor shortage that exists for allogenic whole-
organ transplantation. In addition, this approach would obviate the need 
for immunosuppression.   
 
 
Fig : 13 Organ and tissue Bioengineering 
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An advantage of utilizing the ECM in its native state as a scaffold for 
tissue repair is the presence of all of the attendant growth factors (and 
their inhibitors) in the relative amounts that exist in nature and, perhaps 
most importantly, in their native three-dimensional ultrastructure. It is 
reasonable, therefore, to consider ECM scaffolds as temporary controlled-
release vehicles for naturally occurring growth factors[118].  
Another key advantage of this approach is the ready availability of 
an intact vascular network in the decellularised organs with appropriately 
sized inflow and outflow conduits for anastomosis to the recipient 
circulation and thus perfusion with nutrients and appropriate cues for cell 
behaviour.  
The feasibility of a therapeutic strategy based on cellular 
repopulation of an intact extracellular matrix has evolved as a result of an 
improved understanding of cell–matrix interactions[119-120], 
development of methods for isolation of tissue-specific and organ-specific 
native extracellular matrix with little change in native structure and 
composition[121], rapid advancements of stem cell and progenitor cell 
biology (including the potential use of inducible pluripotent stem cells) 
[122-123], and the integration of the principles of developmental biology 
into regenerative medicine[120]. Although notable scientific and ethical 
challenges remain as this approach advances to clinical use, successful 
proof of principle for organs such as liver[124-125], heart[126], and lung 
[127-130]and complex tissues such as the trachea[131], 
oesophagus[132], and skeletal muscle[133] has been shown. Functional 
restoration of such tissues and organs with matrices might become a 
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viable and practical therapeutic approach to meet future demand after 
organ failure[124-128,131].  
Biologic scaffold materials composed of ECM are commonly used to 
facilitate the constructive remodelling of a variety of tissue  both in 
preclinical animal studies and in human clinical applications[134-137].  
The ECM possesses the ideal characteristics of the tissue-
engineered scaffold or biomaterial, being biocompatible, a supportive 
medium for blood vessels, nerves, and lymphatics and for the diffusion of 
nutrients from the blood, as well as being able to undergo constructive 
remodeling and degradation within the body’s own systems[138-140]. 
All tissues and organs are made up of cells and associated 
extracellular matrix (ECM), a secreted product of the resident cells 
consisting of a unique, tissue-specific three-dimensional environment of 
structural and functional molecules. It is custom designed and 
manufactured by the resident cells of each tissue and organ and is in a 
state of dynamic equilibrium with its surrounding 
microenviromnment[141]. 
The extracellular matrix is a multicomponent structure, a dynamic 
protein network that provides cells with positional and environmental 
information, serving as a tissue-specific structural framework that controls 
cell function. The composition of ECM is represented by a complex 
mixture of functional and structural molecules that affect a variety of cell 
activities[142]. These molecules are arranged in a unique, tissue specific, 
three-dimensional ultrastructure  and are ideally suited to the tissue or 
organ from which the ECM is harvested. The structure and the 
composition of the ECM are constantly changing in response to the 
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current metabolic activity of the resident cell population, the mechanical 
demands of the tissue, and the prevailing microenvironmental niche 
conditions. This concept of “dynamic reciprocity” between the ECM and 
the resident cell population is a major advantage for the use of ECM 
scaffold materials and emphasize the importance of maintaining as much 
of the native composition and ultrastructure as possible during the 
preparation of these three-dimensional scaffolds. Matrix organization and 
its connection to intracellular pathways are important regulators of cell 
function, [143]defects in which can have significant pathological 
consequences [144]. 
Individual components of the ECM are common throughout most 
tissues such as collagen, laminin, fibronectin, and hyaluronic acid.  
Collagen is the most abundant protein within the ECM. More than 20 
distinct types of collagen have been identified and the most prevalent form 
found in mammalian tissues is type I collagen. Collagen has been well 
characterized and is ubiquitous across both the animal and plant 
kingdoms [145]. Collagen has maintained a highly conserved amino acid 
sequence through the course of evolution and for this reason allogeneic 
and xenogeneic sources of type I collagen have been long recognized as 
effective biologic scaffolds for tissue repair with low antigenic potential. 
Collagen types other than type I exist in the native ECM, altought in much 
lower quantities. These alternative collagen types each provide distinct 
mechanical and physical properties to the ECM and contribute to the utility 
of the intact ECM (as opposed to isolated components of the ECM) as a 
scaffold for tissue repair. By way of examples: type IV collagen is present 
within the basement membrane of all vascular structures and is an 
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important ligand for endothelial cells, type VII collagen is the principal 
component of the anchoring fibrils of keratinocytes to the underlying 
basement membrane of the epidermis, and type VI collagen functions as 
a connector of functional proteins and glycosaminoglycans to larger 
structural proteins such as type I collagen, helping to provide a gel-like 
consistency to the ECM. Type III collagen exists within selected 
submucosal ECMs, such as the submucosal ECM of the urinary bladder, 
where nonrigid structure is de- manded for appropriate function.Most 
collagen types cause differentiation of progenitor cell populations. It is 
common, therefore, to find little if any collagen in the ECM surrounding 
ESC populations. 
Fibronectin represents an important noncollagenous component of 
the ECM. Fibronectin exists both in soluble and tissue isoforms and 
possesses many desirable properties of a tissue repair scaffold, including 
ligands for adhesion of many cell types[142,146]. In fact, this protein is 
the first example of a protein recognized to have dual functions, i.e., both 
struc- tural and functional properties. Fibronectin exists within the ECM of 
both submucosal structures and basement membrane structures 
[147,142]. Fibronectin, on the other hand, has been shown to play a 
central role in the development of vascular structures and can be found at 
an early stage in developing embryos. Fibronectin has also been found to 
be critical for the maintenance of hematopoietic stem cell activity ex vivo, 
which is another indication of the important role for this molecule in the 
support of the stem cell phenotype.  
Laminin is a complex adhesion protein found within the ECM, 
especially within the basement membrane form of ECM[142]. This trimeric 
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crosslinked polypeptide exists in numerous forms dependent on the 
particular mixture of peptide chains[148,149]. The prominent role of 
laminin in the formation and maintenance of vascular structures is 
particularly noteworthy when considering the ECM as a scaffold for tissue 
repair[150,151] . Laminin can be found within basement membrane 
structures and is perhaps the best studied of the ECM protein found in 
ESC-derived embryoid bodies[152]. Laminin plays a prominent role in the 
formation and the maintenance of vascular structures and is among the 
first and most critical of the ECM components in the process of cell and 
tissue differentiation.  
Glycosaminoglycans (GAGs) are important components of ECM and 
play important roles in the binding and preservation of growth factors and 
cytokines, water retention, and the gel properties of the ECM. The heparin 
binding properties of numerous cell surface receptors and of many growth 
factors (e.g., FGF family, VEGF) make the heparin-rich GAGs extremely 
desirable components of scaffolds for tissue repair[118].  
The composition of the ECM includes a variety of bioactive 
molecules admixed with the binding molecules such as decorin and 
biglycan. Although cytokines and growth factors are present within ECM in 
extremely small quantities, these molecules act as potent modulators of 
cell behavior.  
The ability of the ECM scaffold to facilitate and integrate cellular and 
external environmental cues is the consequence of its bioinductive 
properties, allowing the important constructive remodeling of tissue after 
the in vivo implantation of ECM scaffolds[153-155]. This remodeling 
cannot be solely attributed to characteristics such as viscoelastic 
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behavior, biomechanical properties, or host cell attachment through 
collagen, fibronectin, and laminin ligands within the ECM. Angiogenesis, 
abundant host cell infiltration, mitogenesis, and deposition and 
organization of new host ECM are common events during the remodeling 
of ECM scaffolds. Component growth factors such as vascular endothelial 
cell growth factor (VEGF), basic fibroblast growth factor (bFGF), and 
transforming growth factor beta (TGF-b) are released during scaffold 
degradation and exert their biologic effects as they are dissociated from 
their binding proteins and activated[156-161]. These growth factors 
promote angiogenesis, mitogenesis and cellular differentiation during the 
remodeling process. The rapid degradation of the native ECM scaffold 
material is mediated by enzymatic and cellular processes and may be 
considered as a mechanism for controlled release of the ECM constituent 
molecules. The degradation process itself, which is mediated by 
enzymatic and cellular processes, may be considered as a mechanism for 
controlled release of the ECM constituent molecules. Indeed, the process 
of scaffold degradation and growth factor release continue until the 
scaffold is completely degraded. Perhaps more importantly, degradation 
products of the parent molecules that constitute the ECM appear to 
mediate a subsequent series of remodeling events. Cryptic peptides 
released by the degradation process initiate and sustain the recruitment of 
circulating, bone-marrow-derived cells that actively parti- cipate in long-
term tissue remodeling[162-163].  
The phenotype of the resident cells, including their active genetic 
profile, proteome, and functionality, is influenced by conditions of the 
microenvironmental niche including factors such as oxygen concentration, 
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pH, mechanical forces, and biochemical milieu. In turn, resident cells 
secrete the appropriate molecules in which to survive, function effectively, 
and communicate with neighbouring cells. Through this reciprocal 
interaction, the ECM has an essential role in prenatal development and 
postnatal maintenance of healthy function[119,120,164,165]. In addition 
to the matrix’s role in development and adult homoeostasis, it can be used 
as an inductive scaffold to promote a constructive tissue remodelling 
response after injury. Mechanisms of this response include release of 
cryptic peptides that are mitogenic and chemotactic for endogenous stem 
and progenitor cells[166-167], modulation of the innate immune 
response[169], and provision of tissue-specific molecular cues that 
support cell phenotype and function[129,169-171].  
 
1.2.1 Principles and methods of decellularisation  
The preparation of a matrix from a large, intact mammalian organ 
requires several sophisticated processing steps. The selection of 
decellularization reagents is critically important because these agents can 
damage the structure and composition of the resultant matrix[172].  
Several factors can affect the ability to decellularize tissues/organs 
which include: (a) the cellular density of a particular tissue or organ, (b) 
the specific density of the tissue/organ, (c) lipid content, (d) thickness of 
the tissue/organ and (e) properties of the selected decellularization 
agent(s) [121]. The most effective agents for decellularization of each 
tissue and organ will depend upon many factors, including the tissue’s 
cellularity (e.g. liver vs. tendon), density (e.g. dermis vs. adipose tissue), 
lipid content (e.g. brain vs. urinary bladder), and thickness (e.g. dermis vs. 
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pericardium). It should be understood that every cell removal agent and 
method will alter ECM composition and cause some degree of 
ultrastructure disruption. Minimization of these undesirable effects rather 
than complete avoidance is the objective of decellularization. 
Detergents, enzymes and chemicals used for whole organ 
decellularization have been used in decellularization for various organs. 
Since decellularization agents can also negatively impact the native ECM 
composition and structure during the decellularization process, selection 
of these agents, along with the development of new protocols, have been 
considered to be critical steps of the process. To achieve this goal, 
several different groups of decellularization agents have been explored 
and such agents include: (a) non-ionic (Triton-X), ionic (sodium dodecyl 
sulfate: SDS) and zwitterionic detergents, (b) enzymatic agents, (c) 
physical agents and (d) direct application of force[121] .  
- Chemical agents  
Acids and bases cause or catalyze hydrolytic degradation of 
biomolecules. Peracetic acid is a common disinfection agent that doubles 
as a decellularization agent by removing residual nucleic acids with 
minimal effect on the ECM composition and structure[173-174]  . Acetic 
acid damages and removes collagens with a corresponding reduction in 
ECM strength, but it does not affect sulfated glycosaminoglycans (sGAG) 
[175]. Bases (e.g. calcium hydroxide, sodium sulphide, and sodium 
hydroxide) are harsh enough and commonly used to remove hair from 
dermis samples during the early stages of decellularization[176-177]  . 
However, bases can completely eliminate growth factors from the matrix 
and decrease ECM mechanical properties more significantly than 
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chemical and enzymatic agents[177]  . The primary mechanism by which 
bases such as sodium hydroxide reduce mechanical properties is the 
cleavage of collagen fibrils and disruption of collagen crosslinks [178].  
Hypertonic saline dissociates DNA from proteins [180]. Hypotonic 
solutions can readily cause cell lysis by simple osmotic effects with  
minimal changes in matrix molecules and architecture . For 
maximum osmotic effect, it is common for the tissues to be immersed 
alternately in hyper- and hypotonic solutions through several cycles. 
Hypertonic and hypotonic solutions also help rinse cell residue from within 
tissue following lysis.  
Ionic, non-ionic, and zwitterionic detergents solubilize cell 
membranes and dissociate DNA from proteins, and they are therefore 
effective in removing cellular material from tissue [179-181]. However, 
these agents also disrupt and dissociate proteins in the ECM as 
evidenced by their use in protein extraction procedures in tissue 
proteomics [182-183]. The removal of ECM proteins and DNA by 
detergents increases with exposure time[184-185]  and varies with organ 
subunit, tissue type, and donor age[186-188]. Combining multiple 
detergents increases ECM protein loss [187]  but also allows for more 
complete detergent removal from ECM after decellularization [188-189]. 
Triton X-100 can effectively remove cell residues from thick tissues such 
as valve conduits where enzymatic and osmotic methods are insufficient, 
with concomitant ECM protein loss accompanied by decreased adverse 
immune response in vivo[191]. Sodium dodecyl sulfate (SDS) appears 
more effective than Triton X-100 for removing nuclei from dense tissues 
while preserving tissue mechanics[186,192]. The addition of a detergent 
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such as SDS to a decellularization protocol can make the difference 
between complete and incomplete cell nuclei removal[193]   but has the 
associated drawback of ultrastructure disruption[194-195]   and growth 
factor elimination [177]. The zwitterionic detergent 3-[(3-
cholamidopropyl)dimethylammo- nio]-1-propanesulfonate (CHAPS) is 
most effective for cell removal from thinner tissues such as lung and may 
be ineffective for decellularization of thicker tissues, even when used in 
combination with SDS[197]   or alone for relatively acellular tissues[185]. 
A blinded categorical comparison of detergents for peripheral nerve 
decellu- larization showed better preservation of ultrastructure by non-
ionic and zwitterionic detergents but better cell removal by ionic 
detergents[198]. However, the low concentration of cell bodies in 
peripheral nerve and the size of the tissue may limit the translation of 
these results to other tissues.  
Care must be taken to flush residual chemicals from ECM after 
decellularization, particularly detergents such as SDS that penetrate into 
thick or dense tissues. Cytotoxicity is possible even at reduced agent 
concentrations and will inhibit or completely negate the beneficial 
properties of a cell-free ECM scaffold[199-200]. Even thin tissues such as 
valve leaflets require multiple (more than six) agitated washes to 
completely remove detergents[197].  
Alcohols such as glycerol aid in tissue decellularization by 
dehydrating and lysing cells instead isopropanol, ethanol, and methanol 
are more effective than lipase in removing lipids from tissue and are 
capable of rendering adipose tissue lipid-free in a relatively brief 
period[201-202]. 
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Methanol in combination with chloroform has been used during 
delipidation of tissues[176].. Caution should be used in treating tissues 
with alcohols such as ethanol and methanol due to their use as tissue 
fixatives in histology, their ability to precipitate proteins[203], and the 
damage they cause to ECM ultrastructure[178-202-203].   
Acetone can also be used to remove lipids during 
decellularization[192]. However, like alcohols, the use of acetone as a 
tissue fixative [203] and its damage of ECM ultrastructure[204] warrant 
conservative use, especially for biological scaffolds used in load-bearing 
clinical applications[178]. In comparison to detergent treatments, acetone 
crosslinks ECM to produce stiffer scaffolds with mechanical properties 
further removed from those of native tissue[192].  
-Biologic agents  
Enzymes reported in tissue decellularization protocols include 
nucleases, trypsin, collagenase, lipase, dispase, thermolysin, and a-
galactosidase. Enzymes can provide high specificity for removal of cell 
residues or undesirable ECM constituents. However, complete cell 
removal by enzymatic treatment alone is difficult and enzyme residues 
may impair recellularization or evoke an adverse immune response.  
Nucleases (e.g. DNases and RNases) cleave nucleic acid 
sequences and can therefore aid in removal of nucleotides after cell lysis 
in tissues[169,184,193,205]. Endonucleases such as benzonase[169] 
may be more effective than exonucleases because they cleave 
nucleotides mid-sequence and thereby more effectively fragment DNA in 
preparation for its removal. Likewise, non-restriction endonucleases will 
more effectively fragment DNA compared to their sequence-dependent 
    
 
 
49
counterparts.  
Trypsin is a serine protease commonly used as an enzymatic 
decellularization agent. However, ECM proteins such as collagens have 
limited resistance to trypsin cleavage[206] and tissue exposure to trypsin 
should therefore be used with caution. In comparison to detergents, 
trypsin is more disruptive to elastin and collagen and slower to remove 
cells but shows better preservation of GAG content[195, 188, 207,208]. 
Trypsin disruption of ECM can be correlated to changes in mechanical 
properties[208]. Removal of cells and ECM constituents by trypsin is time-
dependent, and complete decellularization by trypsin alone may require 
lengthy incubation even for thinner tissues such as valve leaflets[209]. 
Trypsin can be used effectively to disrupt tissue ultrastructure and 
improve penetration of subsequent decellularization agents; therefore, 
exposure to trypsin as the initial step in a tissue decellularization protocol 
may be desirable or even necessary, particularly for complete removal of 
cell nuclei from dense tissues[184].  
Collagenase may be used during decellularization, but only when 
ultrastructure preservation and maximum collagen retention are not critical 
to the intended clinical application of the resultant ECM.  
Lipase aids in delipidation but is typically insufficient to remove all 
lipids when used alone[201-202].  
Dispase and trypsin can be used successively to improve cell 
removal from thicker tissues such as dermis if used in combination with 
detergents, and repeated treatments with dispase may further improve 
decellularization[210]. Using an enzyme such as dispase or thermolysin 
as the sole decellularization agent is only effective for removing cells on 
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the surface of a tissue and is likely to require mechanical abrasion for 
complete cell removal[211]. With regard to the underlying basement 
membrane and ECM, thermolysin is less disruptive compared to 
dispase[211].  
Decellularized xenogeneic tissues can be treated with α-
galactosidase to reduce the immunogenic cell surface antigen galactose-α 
- (1,3)-galactose (Gal epitope) [212], although the immunomodulatory 
effect of Gal epitope does not adversely affect in vivo remodeling of 
xenogeneic ECM[213]. 
-Non-enzymatic agents  
Chelating agents such as ethylenediaminetetraacetic acid (EDTA) 
and ethylene glycol tetraacetic acid (EGTA) aid in cell dissociation from 
ECM proteins by sequestering metal ions[214-215]. It is likely that 
chelating agents contribute to subtle disruptions in protein-protein 
interactions by the same mechanism[216]. Chelating agents alone are 
insufficient for superficial cell removal even with agitation, and they are 
therefore typically used in combination with enzymes such as trypsin[193, 
184,205] or detergents[177,193,196,205]. The combined efficacy of 
chelating agents and simple hyper- or hypotonic solutions for 
decellularization is unknown[193,205,217].  
Serum associates with nucleic acid fragments to aid in their removal 
from tissue, but it does not remove some immunogenic constituents such 
as phospholipids[197]. Additionally, xenogeneic serum has the 
disadvantage of introducing immunogenic constituents that may associate 
with the ECM, thus potentiating a downstream adverse host response. 
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The use of serum in preparing ECM for clinical applications is therefore 
limited.  
Serine protease inhibitors such as phenylmethylsulfonyl fluoride 
(PMSF) [193,201,217], aprotonin, and leupeptin[218] prevent undesirable 
damage to ECM that might otherwise result from release of intracellular 
proteases during cell lysis.  
-Physical and miscellaneous agents  
Freeze-thaw processing effectively lyses cells within tissues and 
organs, but the resulting membranous and intracellular contents remain 
unless removed by subsequent processing. A single freeze- thaw cycle 
can reduce adverse immune responses such as leukocyte infiltration in 
vascular ECM scaffolds[217]. Multiple freeze-thaw cycles may be used 
during decellularization [201-219]and do not significantly increase the loss 
of ECM proteins from tissue. The effect of freeze- thaw processing on 
mechanical properties is minimal for load- bearing, mechanically robust 
tissues[188].  
Cells on the surface of a tissue or organ (e.g., urinary bladder, small 
intestine, skin, amnion) can be effectively removed by mechanical 
abrasion in combination with enzymes[211], hypertonic saline, or 
chelating agents, all of which facilitate dissociation of cells from their 
subjacent basement membrane. However, underlying ultrastructure and 
basement membrane integrity are invariably damaged by any direct 
application of mechanical force[211].  
Hydrostatic pressure requires relatively little time and can be more 
effective than detergents or enzymes for removing cells from blood vessel 
and corneal tissues, although the baric formation of ice crystals may 
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disrupt ECM ultrastructure. [205] Increased temperature during pressure 
decellularization prevents ice crystal formation[205] but may disrupt ECM 
due to the associated increase in entropy, which can be mitigated by 
colloids such as dextran.  
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Fig. 14 scheme of the different agents used in the decellularization protocols. 
 
Unlike agitation and diffusion-only techniques used for the 
decellularization of simple and thin tissues, solid organs require dynamic 
decellularization techniques in order to efficiently remove cellular 
components from the entire organ system. In particular, the mechanical 
forces incorporated with dynamic decellularization techniques are 
important for efficient decellularization. Such mechanical parameters can 
be pressure, shear stress and flow rate of decellularization agents. 
Different levels of mechanical forces need to be applied to 
decellularization processes depending on the size and types of organs. 
Antegrade and retrograde perfusion techniques of the decellularization 
agent(s) through the native vascular system of the organ has been the 
most commonly used method to produce acellular whole organ 
scaffolds[169,172,177,184]. In this approach, perfused decellularizing 
agent(s) are evenly distributed throughout the organ and, in addition, the 
application of a certain amount of pressures during the perfusion process 
has shown to effectively achieve tissue permeation from large blood 
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vessels down to the capillary level. Perfusion of decellularization  solution 
also allows cellular debris to be excreted through the venous system. 
[172] 
 
1.1.2 Characterization of the decellularized tissue 
After the decellularization process, it is necessary to evaluate the 
resulting scaffolds to determine the extent of decellularization and whether 
or not the scaffold is damaged. Assays used for this purpose include 
qualitative and quantitative assays. Qualitative evaluation involves 
demonstrating that cellular material has in fact been removed from the 
matrix as well as demonstrating that the main ECM proteins have been 
retained. This is performed using several different histological and 
immunofluorescent methods. The removal of cellular components by the 
decellularization process can be confirmed by observing the lack of visible 
nuclear material in tissue sections stained with 4, 6-diamidino- 2-
phenylindole (DAPI) or hematoxylin & eosin (H&E). The retention of ECM 
components is visualized by several staining methods, such as Masson’s 
trichrome and Herovici staining for collagens, Alcian blue/PAS staining for 
glycosoaminoglycans (GAGs) and Movat’s staining for collagen and 
elastin fibers. In addition, electron microscopic studies using a scanning 
electron microscope (SEM) and/or transmission electron microscope 
(TEM) are often conducted to examine the decellularized scaffolds on a 
very fine scale to identify ultrastructure within the scaffolds[121].  
However, these techniques are not sensitive enough to identify and 
quantitatively analyze the residual DNA content within the ECM[176]. The 
presence of DNA is directly correlated to adverse host reactions[188,191]. 
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Hence, interest in the quantification of the residual nucleic material after 
decellularization has been justified[176]. Based upon findings from in vivo 
studies in terms of constructive remodeling and adverse host responses 
using two-dimensional decellularized tissues, the following minimal criteria 
for acceptable amounts of residual DNA after decellularization have been 
created[176]: (a) <50 ng double strand DNA per mg dry weight, and (b) 
<200 bp DNA fragment length[188].   
Likewise, the biological activities of ECM components need to be 
considered in the process of whole organ bioengineering. Following the 
decellularization of solid organs, the resulting acellular organ scaffolds will 
be combined with a cellularization technique for further application in in 
vivo studies, and the biological activities of many matrix proteins are 
required for the recellularization step to be successful. First, cell adhesion 
to the acellular organ matrix is a pre-requisite step for the recellularization 
process. In many cases, natural cell-adhesion domain sequences in the 
matrix (e.g., RGD) [204] can bind with members of the integrin family, 
which are expressed on many cell types. This binding is crucial to allow 
cells to adhere to acellular organ matrices. These types of cell adhesion 
peptide motifs exist on ECM components such as collagen and 
fibronectin. Collagen is particularly important because it retains the RGD 
motif as well as bound growth factors. Fibronectin is a representative 
glycoprotein in ECM that plays roles in cell adhesion, growth, migration 
and differentiation[195,203].  
The presence of collagen, fibronectin and laminin is crucial for cells 
seeded onto a decellularized organ to attach to the matrix and begin 
recellularizing the organ.  
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Once seeded cells are attached to the ECM components within 
acellular scaffolds, the behaviors of the cells will be influenced by growth 
factors and bioactive molecules that confer inherent bioactivity within the 
matrix. Generally, growth factors easily degrade after secretion from the 
cells that produce them. However, within the ECM, GAGs are critically 
important in the protection of free growth factors from proteolytic 
degradation[196]. Due to the existence of heparan sulfate residues on 
GAGs and the low isoelectric point (IEP ≈ 5) of heparan sulfate, GAGs are 
able to bind growth factors that have an IEP of ≈10, such as fibroblast 
growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), 
transforming growth factor-β (TGF- β) and platelet-derived growth factor 
(PDGF). Such growth factors become anchored to GAGs and can thus be 
protected from enzymatic degradation. This process allows them to retain 
biological activity, and they can affect cells that bind the various ECM 
compounds during the recellularization of a decellularized organ scaffold. 
Another role of GAGs for the recellularization process is of particular 
importance in morphogenesis which promotes cellular adhesion 
permissive cell shape changes and motility as well as the maintenance of 
original phenotypes of repopulated cells[221]. Hyaluronic acid (HA), one 
subset of GAGs, is such a molecule. HA is considered to be important for 
several aspects of cellular behaviors such as the direction of cellular 
shape changes and the induction of cytoskeletal rearrangements within 
cells. However, during current decellularization processes, 50 to 90% 
amounts of GAGs in various organs [222,223] were reported to be 
removed when compared to that of original organs. The reduction of GAG 
amounts may cause the inactivation of endogenous growth factors and 
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also adversely influence the efficient recellularization process due to lack 
of primary components of GAGs. Further investigations may be needed 
into the modification of decellularization method for the maintenance of 
GAG architectures after decellularization.  
Just as solid organs have an intricate vascular tree within them, 
acellular organ scaffolds should maintain continuous and intact vascular 
structures after the decellularization process. This vascular matrix can be 
used to reseed the matrix for efficient whole organ bioengineering. This 
vascular system can be used as a template for cell seeding with organ- 
specific types of parenchymal cells or it can be directly seeded with 
endothelial cells. This is especially important because a continuous and 
functional re-endothelialized vascular system within a recellularized whole 
organ can reduce thrombosis and blood clots when the organ is integrated 
with the vasculature of the host during the implantation procedure.  
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1.2.3 State of the art of the different decellularization 
scaffolds 
Intact three-dimensional extracellular matrix scaffolds from different 
allogeneic and xenogeneic tissues and organs have been manufactured 
effectively for regenerative medicine. 
 
Fig.15 Some reported perfusion protocols for decellularization of heart, liver and lung. Abbreviations: DMEM, 
Dulbeccos’s Modified Eagle’s Medium; EDTA, ethylene diamine traacetic acid; FBS, fetal bovine serum; PBS, phosphate buffered 
saline; SDS, sodium dodecyl sulfate. 
 
 
The heart 
 
The first report in which whole-organ decellularization was 
successfully performed was on the heart[222]. The aorta of a rat heart 
was cannulated to allow retrograde coronary perfusion with heparinized 
phosphate-buffered saline with adenosine, 1% sodium dodecyl sulfate 
(SDS), and 1% Triton X-100 in sequence alternating with rinsing with 
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deionized water between steps. This produced a decellularized scaffold 
that was structurally similar to the heart, but had a translucent white 
appearance throughout (Fig. 16). Reimplantation of the acellular heart 
scaffold onto the aorta demonstrated an intact and patent vascular 
network . 
Recellularization of the heart scaffold with cardiomyocytes under 
electro- physiological stimulation formed a construct capable of muscular 
contraction[126].  
 
Fig. 16 The heart in stages of increasing decellularization over time with 1% sodium dodecyl sulfate as the decel- 
lularizing agent, with the end result of a translucent ap- pearing heart-like scaffold structure. The panel on the right shows 
histological evidence (H&E staining) of decellu- larization. Scale bar = 200 mm.  
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The lungs  
A number of groups have investigated the use of perfusion 
decellularization in the lungs[128,129,194,223,224], which contain two 
accessible compartments separated by a short diffusion distance, that is, 
the vascular and the airway systems, by using varying protocols of 
vascular perfusion alone[194,224], or in combination with endotracheal 
instillation[128,223], or perfusion of the airway compartment[129]. The 
decellularizing agents used were also far more varied from protocol to 
protocol, from SDS at different concentrations [129,198,224]  to 8mM 
CHAPS[128], to a combination of Triton X-100/deoxycholate/ 
DNAse/bleach[223]. All groups demonstrated preservation of the major 
components of the ECM and the micro- and macroarchitecture of the lung. 
Recellularization was achieved with all the reports, although 
Petersen et al. mimicked physiological conditions within the bioreactor by 
ventilation of the airway compartment at negative pressure at 1 
breath/min, and maintained pulmonary artery pressure at 20 mmHg or 
below. Orthotopic implantation of these tissue-engineered lung constructs 
demonstrated active gas exchange occurring via sampling of pulmonary 
arterial and venous blood. 
However, results in this study and Ott et al. showed vascular 
leakage and pulmonary edema after a few hours of implantation, 
indicating damage to the microvasculature from the decellularization 
process. In a follow-up study to Ott et al., Song et al. demonstrated further 
optimization of graft preservation and oxygenative function post-
implantation for as long as 7 days[224]. Recellularization was performed 
with mixtures of whole-lung cell isolates in four cases[128,194,223,224], 
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but one group used a homogeneous mouse embryonic stem cell 
population[129], which showed that the matrix was capable of promoting 
site-appropriate differentiation without any other specific differentiation 
cues.  
 
 
Fig. 17 Perfusion decellularization of whole rat lungs. (a) Photographs of a cadaveric rat lung, mounted on a 
decellularization apparatus allowing antegrade pulmonary arterial perfusion. pa, pulmonary artery; pv, pulmonary vein; tr, trachea; 
RUL, right upper lobe; RML, right middle lobe; LL, left lobe. Freshly isolated lung (left), after 60 min of SDS perfusion (middle), 
and after 120 min of SDS perfusion (right). The lung becomes more translucent as cellular material is washed out first from apical 
segments, then from the middle segments and finally from the basal segments. 
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The liver  
Liver decellularization has been performed by antegrade perfusion 
via the portal vein with SDS and Triton X-100, either alone or in 
combination [124, 225-227], although another study used 
trypsin/EGTA[185], and Baptista et al. used Triton X-100 in combination 
with ammonium hydroxide[177, 228]. Decellularization was demonstrated 
with histology and evidence of DNA removal, and retention of key ECM 
constituents with preservation of microvasculature and ECM 
ultrastructure. Hepatocytes were seeded onto the acellular liver scaffold 
via portal vein perfusion and were shown to be functional in four studies 
[177,225,227-228]by showing evidence of synthesis of lactate 
dehydrogenase, albumin, and urea after heterotopic implantation. In 
particular, two studies attempt to scale-up this approach to further 
approximate human- scale engineered organ constructs by use of 
ferret[177] and porcine[227] livers, and both studies seeded the 
bioscaffolds with human liver cells, which were shown to be compatible on 
these xenogeneic scaffolds.  
 
 
Fig. 18 Decellularization of ischemic rat livers. (a–e) Representative images of ischemic rat livers during 
decellularization process at 0 h (a), 18 h (b), 48 h (c), 52 h (d) and 72 h (e).  
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The kidney 
Several groups have decellularized whole kidneys by the perfusion 
method with preservation of the vascular network and complete cell 
removal[228-230]. Decellularizing agents vary from 1% Triton or 
SDS[228-229] to 3% Triton with DNase and additional 4% SDS[230]. The 
preservation and presence of ECM constituents such as laminin and 
collagen IV were also demonstrated, as well as collagen I, fibronectin, and 
heparin sulfate in a separate study, which did not employ perfusion[208]. 
The latter study juxtaposed fetal cells in fresh renal explants with the ECM 
scaffolds by layering fetal kidney tissue against the ECM, which supported 
developmental renal phenotypes in these cells after they migrated into the 
ECM. In the study by Ross et al., decellularized rat kidneys scaffolds were 
reseeded with murine embryonic stem cells, and the renal ECM was 
shown to support the renal differentiation of the embryonic stem cells.  
The last but not the least Ott et al. decellularized rat, porcine and 
human kidneys by detergent perfusion, yielding acellular scaffolds with 
vascular, cortical and medullary architecture, a collecting system and 
ureters. 
To regenerate functional tissue, they seeded rat kidney scaffolds with 
epithelial and endothelial cells and perfused these cell- seeded constructs 
in a whole-organ bioreactor. The resulting grafts produced rudimentary 
urine in vitro when perfused through their intrinsic vascular bed. When 
transplanted in an orthotopic position in rat, the grafts were perfused by 
the recipient’s circulation and produced urine through the ureteral conduit 
in vivo. [231] 
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Fig. 19 Perfusion decellularization of whole rat kidneys. (a) Time-lapse photographs of a cadaveric rat kidney 
undergoing antegrade renal arterial perfusion decellularization. Shown are a freshly isolated kidney (left) and the same kidney 
after 6 h (middle) and 12 h (right) of SDS perfusion. Ra, renal artery;Rv, renal vein; U, ureter.  
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Trachea 
Macchiarini et al. repopulated a decellularized human windpipe in a 
bioreactor whit cultured auologus respiratory ephitelial cells and autologus 
chondrocytes of bone marrow-derived mesenchymal stromal cell origin, 
and used the resultant graft to replace a terminally diseased left main 
bronchus. 
For the decellularization technique they used 25 cycle of distilled 
water for 72 h, then incubated in 4% sodium deoxycholate and 2000 kU 
deoxyribonuclease I in 1 mmol/L sodium chloride (Sigma Chemicals, 
Barcelona, Spain). [131] 
 
 
Fig. 20 The graft obtained after the decellularization process and immediately before the implantation. 
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SIS (small intestinal mucosa) 
Totonelli et al in 2012, using a detergent-enzymatic treatment (DET), 
optimized in rats a protocol that creates a natural intestinal scaffold, as a 
base for developing functional intestinal tissue. After 1 cycle of DET, 
histological examination and SEM and TEM analyses showed removal of 
cellular elements with preservation of the native architecture and 
connective tissue components.This DET consists of deionized water at 4 
°C for 24 h, 4% sodium deoxycholate (Sigma) at room temperature (RT) 
for 4 h, and 2000kU DNase-I (Sigma) in 1 M NaCl (Sigma) at RT for 3 h, 
as previously descrive also for trachea. Maintenance of biomechanical, 
adhesion and angiogenic properties were also demonstrated strengthen 
the idea that matrices obtained using DET may represent a valid support 
for intestinal regeneration[131].  
 
Fig.21 Decellularization of rat small intestine with detergent-enzymatic treatment. Macroscopic pictures prior (A) and 
following (B) one cycle of decellularization. 
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Thyroid 
Working in the laboratory of Regenerative Morphology and 
Bioartificial Structures at the S.Bi.BI.T Department of the University of 
Parma, under the supervision of Prof. Roberto Toni, I have been engaged 
in developing a protocol for decellularization of the rat thyroid. We settled 
a protocol based on freeze and thaw, 0.02% of trypsin, 3% of Triton X-100 
in PBS, 4% of Sodium deoxycholate in PBS and final sterilization with 
Peracetic Acid. After tissue process the structure of the matrix remained 
intact , in terms of 3D-structure, and at the same time the matrix obtained 
was very well cleaned in DNA. 
We also collected preliminary results on the recellularization  of this 
scaffold, using a culture model with cells derived from the same animal 
source, the rat thyroid.  As a result, we observed that after 7 days of 
culture the thyroid matrix provided attachement of the seeded cells, and 
maintenance of their differentiation state [233]. 
 
Fig.22 Decellularization of rat thyroid with detergent-enzymatic treatment. Macroscopic pictures prior in situ (A) and ex 
situ (B) following (C) decellularization protocol. 
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1.3 Culture of thymic epithelial cells  
 
Culturing thymic epithelial cells in vitro, freshly obtained from the 
tissue, is a problem of substantial interest. 
In vivo, Thymic ephitelial cells undergo a rapid expansion during the 
early stages of thymus development, but as lymphopoiesis progresses, 
the more mature ephitelial cells exit the cell cycle to leave only thymic 
ephitelial stem cell pool. 
Monolayer cultures of thymic stromal cells have been used for in 
vitro assays of stromal cell function. Immortalization techniques have 
been used in conjuction with monolayer culture to generate long term 
stromal cell lines and it has been shown that monolayer cultures are 
capable of inducing the maturation of CD4- CD8+ CD3-  cells from their 
CD4- CD8- CD3- precursors. 
Thymic ephitelial cell lines have also been used to induce a limited 
growth and differentiation of early thymic precursors cells in coculture. 
A number of studies have shown that thymic stromal cells cultured 
as monolayer rapidly loose their ability to support T-cell development, 
suggesting a change in their normal phenotype. 
They change their normal phenotype in a serum free medium, 
altought fetal calf serum or human serum has been used as a necessary 
constituent of the culture medium but this has several disadvantages such 
as the addiction of unknown factors (hormones, endotoxins, viruses and 
other macromolecules) [234], which may vary from batch to batch. This 
creates problems of reproducibility but also makes it difficult to define 
growth requirements for the cells, and to isolate and figure out the 
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meaning of biological activities executed by molecules released by the 
cells into the culture medium [235]. 
It has been reported that for growing of murine TEC is essential the 
ephidermal growth factor, insulin and hydrocortisone [236] instead,  for 
human TEC, it’s important the supplement of selenium, transferrin  and 
insulin to the culture media. [237-238] 
There are also some different way to culture thymic ephitelial cells 
using not only a specific media but doing coculture with other cell type that 
could support TEC.  
In 1986, Ehmann at al., cultured TEC, using  a tissue culture plastic, 
were plated togheter with letally irradiated cells of the LA7 rat mammary 
tumor line that gave a support for growing. Ephitelial cells from the normal 
mouse thymus could be cultured and subcultured for at least 8 passages 
in this way. As the irradiated LA7 cells slowly decreased in number TEC 
proliferated concomitantly to form a confluent monolayer like show in 
figure 23. [239]  
 
 
Fig.23  An image of a colony of distinct thymus cells with LA7 cells near the top of the image. Magnification X89 . 
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1.3.1 Three dimensional culture of thymic epithelial 
cells 
Culturing thymic ephitelial cells in vitro preserves the ability of these 
cells to promote thymocytes maturation so long as they are cultured as 3-
dimensional aggregates. The 3-dimensional structure of the thymic 
ephitelial cells is essential to maintain their function within the intact 
thymus.  
The correct 3-dimensional structure therefore appears to be a pre-
requisite for full ephitelial cell function in vitro since the 3D thymic 
architecture contributes to critical cell-cell interactions.  
3D matrices were created by culturing thymic fragments  on the 
surface of disks  of CellFoam (Cytomatrix) and this resulted in the 
colonization with thymic stromal cells reaching 80% of confluency [240]. 
This matrices were then used with the addition of progenitor cells 
CD34+ or AC133+  and a coculture for 14 days demonstrated that these 
matrices were capable to induce a differentiation in the progenitor cells 
and they were able to high proliferate in the presence of interleukin 2 and 
phytohemagglutinin [241]. 
There was also some way of doing a coculture in a 3D structure like 
a three dimensional organotypic coculture model. This was used for the 
culture of isolated mTECs to mimic a dermal equivalent in vitro. It 
consisted of dermal fibroblast that were embedded in a inert scaffold 
consistuted by fibrin gel like shown in Fig. mTEC seeded on top of this 
fibrin gel proliferated and underwent terminal differentiation. This three 
dimensional model preserves key features of mTECs: proliferation and 
terminal differentiation of CD80lo , Aire- mTECs into CD80lo , Aire+ mTECs, 
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responsiveness  to RANKL and sustained expression of FoxN1, Aire and 
tissue-restricted genes into CD80hi mTECs [242]. 
  
Fig.24  A schematic rapresentation of the 3D organotypic coculture. 
Less it has been done for the reconstruction of the thymus, in vitro 
and then in vivo, since it has been demonstrated that after injection of IL-
22 after chemioterapic treatment is enough in the regeneration of thymic 
epithelium.  
IL-22 has been identified as an important player in the thymic 
regeneration. It appears to be mainly produced by thymic  innate lymphoid 
cells in response to tissue damage, and this process is at least partly 
regulated by dendritic cells throught the production of IL-23. The receptor 
for IL-22 is expressed on TEC and seems to induce their survival and 
proliferation[243].  
In 2002, Gill et al, identified a population of MT24+ cells, a 
subpopulation of TEC. These cells contained epithelial progenitor cells 
that were competent and sufficient to fully reconstitute the complex thymic 
ephitelial microenvironment that supported normal T cell development. 
This population has been cultured for 24 hours and then, after 
reaggregation, it has been implanted under the kidney capsule of 
congenic recipient mice. These reaggregates were able, after 3 weeks, to 
induce the maturation of pre T-lymphocytes in a comparable situation to 
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the normal thymic tissue[241].  
In 2012, Piccinini et al, developed an in vitro 3D module to culture 
TEC. They were cultured in different 3D shape with a scaffold made up 
fibrin and they identified like a best shape a simple drop in which cells are 
embedded. In this configuration TEC were able to maintain their 
differentiated state like underlined by the expression of a series of marker 
that were expressed in a comparable quantity to the in vivo situation. They 
maintened their phenotype after 14 days in vitro and, after coculture with 
pre-T lymphocytes, they were able also to induce the maturation of them 
in a more differentiated phenotype[244]. 
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2.AIM OF THE THESIS 
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2. AIM 
 
The aim of my experimental work has been to develop an innovative 
technique to reproduce in vitro the 3D thymic microenvironment, to be 
eventually used for growth and differentiation of  thymocytes, and possible 
transplantation replacement in conditions of depressed thymic immune 
regulation. The work has been developed in the laboratory of Tissue 
Engineering at the University Hospital in Basel, Switzerland, under the 
tutorship of Prof.Ivan Martin, Director of this research Center.  
Since a number of studies have suggested that the 3D structure of 
the thymic microenvironment might play a key role in regulating the 
survival and functional competence of thymocytes, I’ve focused my effort 
on the isolation and purification of the extracellular matrix of the mouse 
thymus, choosen as a suitable research model. Specifically, based on the 
assumption that TEC can favour the differentiation of pre-T lymphocytes, 
I’ve developed a specific decellularization protocol to obtain the intact, and 
DNA-free extracellular matrix of the adult mouse thymus. In this manner, I 
have tried to prevent the cytotoxic effect of contaminating nucleic acids on 
seeded TECs, and to provide a functional 3D structure rich in intrinsic 
proteins for TEC growth and assembly.   
This 3D matrix, then, has been used as a natural scaffold for 
culturing TEC in static conditions.  In particular, I have analyzed a number 
of surface markers indicating TEC capability to maintain their own 
phenotype, and eventually promote the differentiation of pre-T 
lymphocytes, similar to what previously demonstrated with other 3D 
structure like the fibrin gel.  
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3.MATERIALS AND METHODS 
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3.1 TECs isolation 
 
3.1.1 Thymi digestion 
 
TECs are isolated from B6 mice, 4-6 weeks old. 
Thymus isolation and cleaning is performed on the lab bench, 
while the digestion is performed in sterile conditions under the hood. 
Mice are sacrificed by cutting the head to avoid CO2 and 
excessive bleeding in the thymic area.  
The mouse is open cutting the peritoneum, cutting the membrane 
separating the chest from the peritoneum, cutting the ribs and exposing 
heart and thymus. 
The thymus is isolated by pulling it, without cutting, and after it is 
placed in a Petri dish on ice containing PBS + 2%Fetal Bovine Serum. 
After the explant and before the digestion, Thymi are cleaned, 
under the microscope, by fat and capsule to facilitate enzymes’ action in 
a solution of  
The thymi are cleaned under the microscope. First lobes are 
separated and then each lobe is cleaned from fat and connective tissue. 
Finally to favor the digestion small holes are done in the capsule. 
The digestion is carried out in a water bath at 37°C in an 
enzymatic solution made of PBS, Liberase (Product 
Number:05401127001 Roche Diagnostic) and DNase (Product 
Number:11284932001 Roche Diagnostic). 
For 6 thymi the solution is made of: 
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Liberase: 50mg/20 ml H2O sterile 500µl 
DNase: 10mg/1 ml H2O sterile 50µl 
PBS: 5,5 ml 
 
The thymi are left at 37°C for ten minutes. Then the solution with 
pieces are pipetted up and down with a tip of 1000µl ,cut before to favor 
the digestion. This is done for two times. 
The pellet is allowed to sit down, the supernatant with cells is 
collected and enzymes are inactivated added to them IMDM+ 2%Fetal 
Bovine Serum. 
3ml of the digest solution is added to pellet and left at 37°C for ten 
minutes. Then the solution with pieces are pipetted up and down with a 
tip of 1000µl ,cut before to favor the digestion. This is done for two 
times. 
After these steps all pieces are digested and enzymes are 
inactivated added to solution IMDM+ 2%Fetal Bovine Serum. 
Two solutions, coming from first and second digestion 
respectively, are pooled down together at 1500 rpm 5’. 
Cells are resuspended in 10ml of PBS + 2%Fetal Bovine Serum 
and filtered through a 70 µm strainer. 
10µl of the solution is used to count cells at the Cell Coulter. 
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Fig.25  An image of the cell coulter.  
For the counting 10µl of solution with cells is added to 10ml of 
PBS and 3 drops of Zap-oglobin. 
The result obtained on Cell Coulter is multiplied per 2 and per 103 
per the ml of the solution. 
The solution is adjusted to bring cells to a concentration of 
100x106 cells. 
 
 
 
3.1.2 CD45 depletion 
The cells’ solution freshly obtained is used for CD45 depletion. 
CD45 beads (Product Number:130-052-301 Miltenyi Biotec)  are added 
to cells at a concentration of 5µl/107 cells.  
The solution is left 15’ at 4°C in the dark. 
After that cells are washed 2 times with PBS + 2%Fetal Bovine 
Serum spinning down at 1500rpm 5’.  
Cells are filtered through a 70 µm strainer and then distributed in 
FACS tubes (2ml each tube)  after another filtration through a 45 µm 
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strainer attached to a 2,5 ml syringe. 
 
Fig.26  A image prior the filtration of the cell suspension. 
The enrichment can start with the AutoMACS Pro Separator 
System(Miltenyi Biotec ) using the protocol Deplet_s + QRinse. 
 
 
Fig.27  A image of the AutoMacs used for the CD45 depletion. 
Cells of interest will be in the CD45- fraction. These cells are 
spinned down at 1500rpm 5’ and the pellet is resuspeded in 1ml of 
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Iscove’s Modified Dulbecco’s Medium(IMDM) (Gibco; Invitrogen) 
containing 10% FCS, β-mercaptoethanol and Kanmycin (Gibco; 
Invitrogen) and again counted as described above. 
 
3.1.3 TECs purity 
75 µl of total cells obtained are used to check the purity. 
The 75 µl of solution are brought to 1ml with PBS + 2% FBS. To 
the tube are added directly the two antibodies: 
EpCam Alexa 647(1:2000) (Product Number:118211 BioLegend) 
CD45 Alexa 700 (1:20) (Product Number:103127 BioLegend) 
The solution is incubated 15’ a 4°C, then centrifugated and 
resuspended in 300µl of  PBS + 2% FBS. A filtration is performed 
through a 45 µm strainer attached to a 2,5 ml syringe and then 100µl of 
DAPI (Product Number:422801 BioLegend) are added and all is 
acquired at FACS Aria.  
 
 
Fig.28  FACS Aria used for FACS analysis. 
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TECs purity usually goes from 20% to 30% of total cells obtained. 
 
3.1.4 Culture medium and supplements 
TEC were cultured in CnT-57 cell culture medium (CELLnTEC, 
Bern, Switzerland). CnT-57 is a progenitor cell target liquid culture 
medium with low calcium concentration (0.07mM) and low concentrated 
Bovine Pituitary extract (BPE) (6µgr/ml). CnT-57 is a protein free 
medium containing a variety of amino acids, minerals, vitamins and 
other factors such as Fibroblast Grow Factor (FGF), Epidermal Growth 
Factor (EGF), and Insulin. 
Additionally, the culture medium was supplemented with 10nM 
dihydrochloride monohydrate, a cell permeable anti-apoptotic selective 
Rho-associated Kinase (ROCK) Inhibitor (10nM; Calbiochem, Merk) to 
enhance viability. Kanamycin was supplemented to the medium to 
reduced potential hazard of contamination. 
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 3.2 DNA Quantification 
Samples were dried onto sterile paper and weighted. Samples 
were then frozen at -20°C. 
The day before the analysis, samples were put in a solution of 
Proteinase K at 56°C, until complete digestion. Usually overnight is 
enough to digest the entire sample. 
This lysis solution contains: 
Proteinase K: 1mg/ml in 50mM Tris pH 7.6 (SIGMA-ALDRICH 
Product Number:P2308) 
Pepstatin A: (SIGMA-ALDRICH Product Number:P5318) 
EDTA 100mM+Iodoacetamide 100mM (Siegfried) 
TRIS: (SIGMA-ALDRICH Product Number:A5456-3) 
DMSO: (FLUKA Product Number:41640) 
The day after the digestion: 
Thaw the CyQUANT® Cell Proliferation Assay Kit (InVitrogen 
Product Number:C7026) 
a. Preparation of the working buffer 
! Dilute Component B (20x): 20 ml = 1 ml Component B + 19 ml 
H2O 
! Add Component A (400x) to the same tube 50 µl / 20ml 
 The component A is light sensitive so you have to wrap the tube in 
an aluminum sheet 
b. Preparation of DNA working solution 
! Bovine DNA: Stock solution 10 µg/ml  
    
 
 
83
! DNA working solution : 1 µg/ml Dilution 1/10 
c. Preparation of the standards 
For each standard we need: 3 x 200 µl so we prepare 640 µl 
d. Preparation of the standard curve: (use the black plates) 
Each standard will be done in triplicate: Pipette 200 µl/well for each 
standard  
e. Preparation of the samples 
     Dilution 1/200:  5 µl sample   directly to the well 
                    + 195 µl working Buffer  directly to the well 
When all the samples are pipetted, cover the plate with an 
aluminium paper 
f. Reading of the values 
   Use the Perking Elmer HTS 700 apparatus, and a protocol with a 
wavelength of 480/520nm. 
 
Results were normalized for the weight, and compared using the 
bar graph. 
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3.3 SEM Analysis 
 
 Samples were fixed and dehydrated following this sequence: 
• Rinse in PBS for 10 min 
• Formaldehyde 4% overnight 4 ° C  
• 2X rinse in PBS for 10 min 
• 3X 20 min 30% Ethanol  
• 3X 20 min 50% Ethanol 
• 3X 20 min 70% Ethanol  
• 3X 20 min 90% Ethanol  
 
Tissues were transferred to 100% ethanol, subjected to Critical Point 
Drying, and covered with gold particles. 
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3.4 Istochemistry 
 
3.4.1Hematoxylin and Eosin Staining 
Samples were fixed by immersion with Paraformaldehyde 4% for 
12 hours at 4°C, and then put in Sucrose(Sigma Aldrich Product 
Number:  
S7903) 30% in Milli Q water. 
After that, samples were put in the embedding machine for the 
alcohol dehydratation and the final step in liquid paraffin at 60°C.  
When samples were in liquid paraffin, were embedded and then cut 
with the microtome in slides of 6µm using polylisinate glasses.  
Then slides were dried at 37°C overnight and put in the staining 
machine. 
The staining includes these phases: 
 
• Ultraclear 90s (Biosystem Product Number:41-5213-00) 
• Ultraclear 90s 
• Ultraclear 90s 
• Ethanol 100% 90s 
• Ethanol 100% 90s 
• Ethanol 96% 90s 
• Ethanol 70% 90s 
• Ethanol 50% 90s 
• H2O distilled 90s 
• HE mayer 90s (Biosystem Product Number:38-7010-00) 
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• HE mayer 90s 
• HE mayer 90s 
• H2O tap 90s 
• HCl -Alcohol 0.2% 90s 
• H2O tap + NH4 90s 
• Eosin 0.2% 90s (Biosystem Product Number:38-7410-00) 
• Eosin 0.2% 90 s 
• Eosin 0.2% 90s 
• Ethanol 96% 90s 
• Ethanol 96% 90s 
• Ethanol 100% 90s 
• Ultraclear 90s 
• Ultraclear 90s 
• Ultraclear 90s 
 
Slides were mounted with Mounting medium (Pertex Product 
Number:41-4012-00), and acquired at different magnification with an 
Olympus DP80 light microscope. 
 
 
3.4.2 Immunohistochemistry 
The immunoistochemisty it has been used to evaluate the presence of 
specific proteins in tissues analized: 
Antibody anti-Collagen type IV (AbCam Product Number:ab6586) 
Antibody anti-Fibronectin (AbCam Product Number:ab2413) 
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• Ultraclear 10m (Biosystem Product Number:41-5213-00) 
• Ultraclear 10m 
• Ethanol 100% 5m 
• Ethanol 95% 1m 
• Ethanol 70% 1m 
• Ethanol 35% 1m 
• Rinse with buffer TBS 1X 1m 
• Rinse with buffer TBS 1X 1m 
• HEAT MEDIATED ANTIGEN RETRIEVAL 
• Retrieval solution (Dako Product Number:S1700) 10m at 95°C 
• Let it cool down for 10-15m 
• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• BLOCKING  
• Goat serum ( Invitrogen Product Number:16210-064) 10m 
• Rinse with buffer TBS 1X 5m 
• Primary antibody diluted in TBS 1%BSA overnight at 4°C 
• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• Secondary antibody diluted in TBS 1%BSA 1:200 45m (polyclonal 
Goat anti Rabbit Immunoglobulins/HRP E0432) 
• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• DAB 5 m (1 tablet in 15ml of TBS1X plus 12 µl of 30% H2O2)  
( Sigma Aldrich Product Number:D5905) 
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• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• Rinse with tap water 1m 
• Hematoxylin 20s 
• Rinse with tap water 1m 
• Ethanol 96% 90s 
• Ethanol 96% 90s 
• Ethanol 100% 90s 
• Ultraclear 90s 
• Ultraclear 90s 
• Ultraclear 90s 
Slides were mounted with Mounting medium (Pertex Product 
Number:41-4012-00), and acquired at different magnification with an 
Olympus DP80 light microscope. 
 
Antibody anti-Laminin (AbCam Product Number:ab128053) 
• Ultraclear 10m (Biosystem Product Number:41-5213-00) 
• Ultraclear 10m 
• Ethanol 100% 5m 
• Ethanol 95% 1m 
• Ethanol 70% 1m 
• Ethanol 35% 1m 
• Rinse with buffer TBS 1X 1m 
• Rinse with buffer TBS 1X 1m 
• ENZYMATIC DIGESTION 
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• Trypsin 0,1% in TBS ( Gibco Product Number:15090-046) 
• BLOCKING  
• Goat serum ( Invitrogen Product Number:16210-064) 10m 
• Rinse with buffer TBS 1X 5m 
• Primary antibody diluted in TBS 1%BSA overnight at 4°C 
• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• Secondary antibody diluted in TBS 1%BSA 1:200 45m (polyclonal 
Goat anti Rabbit Immunoglobulins/biotinylated E0432) 
• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• Vectastain ABC/AP kit (Linaris Product Number:AK-5000) 45 m in a 
humid chamber 
• Rinse with buffer TBS 1X 5m 
• Rinse with buffer TBS 1X 5m 
• Vector Red AP substrate + Levamisole (Linaris Product Number: SK-
5100) 
• Rinse with buffer TBS 1X 1m 
• Rinse with tap water 1m 
• Hematoxylin 20s 
• Rinse with tap water 1m 
• Ethanol 96% 90s 
• Ethanol 96% 90s 
• Ethanol 100% 90s 
• Ultraclear 90s 
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• Ultraclear 90s 
• Ultraclear 90s 
Slides were mounted with Mounting medium (Pertex Product 
Number:41-4012-00), and acquired at different magnification with an 
Olympus DP80 light microscope. 
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3.5 Reagent for the decellularization process 
• Triton X-100 (Sigma Aldrich Product Number:T8532) 
• Sodium Deoxycholat (Sigma Aldrich Product Number:30970) 
• DNAse I from Bovine Pancreas (Sigma Aldrich Product 
Number:D4263) 
 
3.6 MTT assay 
The yellow tetrazolium salt (MTT) (Sigma Aldrich Product Number: 
M5655) is reduced in metabolically active cells to form insoluble 
purple formazan crystal, which are solubilized by the addition of a 
detergent.  
 
1. Weight 12.5 mg  
2. Dilute it in 25 mL culture medium w/o phenol red. 
3. Filter sterilize = MTT stock solution (0.5mg/ml), storage in the 
freezer  
4. Dilute 1/10 of MTT stock solution with culture medium w/o 
phenol red = MTT working solution (0.05mg/ml=50ug/ml) 
5. Remove culture medium from your wells 
6. Rinse with PBS 
7. Add MTT working solution (to cover the sample)  
8. Keep in incubator for about 2 hours 
9. Remove MTT working solution 
10. Rinse with PBS 
11. Look at the distribution of the cells in the scaffold 
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3.7 Scaffold preparation 
 
• Dry the scaffold on paper to let it dry for the disruption  
• The scaffold is put into cryovial with metal beads inside given with the 
machine itself (Mikro-Dismembrator).  
• The vials were freezed in dry ice to let the scaffold hard and more 
easy to disrupt  
• After 10 minutes the vials were transferred into the Mikro-
Dismembrator S  
• The scaffold were disrupted at 3000 rpm for 1 minute.  
• the product of dismembration is a powder that is subsequently 
dissolved in 200 µl per thymus of MilliQ water  
• 50 µl of the solution are distributed for each well of 96 well  
• the 96 well is directly freezed at -20°C 
• after 2 hours the weel is transferred into the lhyophilizator 
• it is set at a pressure of 0.0030mbar and a temperature of -50°C  
• the sample are left overnight for drying 
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4. RESULTS AND DISCUSSION 
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4.1 STUDY OF A PROTOCOL FOR THYMUS 
DECELLULARIZATION 
 
To obtain an efficient protocol to decellularized the murine thymus, I 
started to apply a protocol, previously developed for the rat thyroid. It 
consists of different steps, detailed in the table below. 
Freze and thaw  
Trypsin 0.05% 30 minutes at 37°C 
Triton X-100 3% 48 hours 
Deoxycholic acid 4% 24 hours 
PBS 30 minutes at 4°C 
Peracetic acid 0.1 % 3 hours at RT 
PBS 48 hours 
 Table 1. protocol of thyroid decellularization applied to mouse thymus 
 
The obtained matrices were analyzed to determine the extent of 
decellularization, if the cellular material had been thouroughly removed 
and wheter or not the scaffold tissue was damaged. For this purpose 
Haematoxylin and Eosin (H&E) staining and SEM analysis were 
performed. 
 
  
Fig.29 H&E staining of decellularized thymus at 10X and 20X of magnification 
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Fig.30 SEM analysis of the matrix obtained at two different magnification 
 
These analysis showed that the protocol initially is too aggressive for 
the mouse thymus and it damaged the structure and the compositions of 
its ECM when compared to the native one. 
 
  
Fig.31 H&E staining of native thymus at 4X and 20X of magnification 
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 Fig.32 SEM analysis of the native thymus at two different magnification. At higher magnification is possible to see some 
limphocytes on the surface of the organ itself. 
 
Starting from this point, I’ve analyzed the role played by different 
agents used in the protocol and their activity on the mouse thymus.  
Thymic matrices were decellularized using the same protocol but 
eliminating one by one the different solutions to evaluate the action of the 
different agents on the ECM. 
The different agents evaluated has been: Triton X-100 3%, 
Deoxyxholic Acid 4%, Trypsin 0,05% and 0,01%. The matrix structure was 
evaluated by H&E staining, SEM and DNA quantification to figure out the 
influence of these agents on the ECM of the thymus and its 3D structure. 
In the following table is described the first modified protocol tested 
on the mouse thymus to evaluate the action of the Deoxycholic acid on 
the ECM. 
 
Freze and thaw  
Trypsin 0.05% 30 minutes at 37°C 
Deoxycholic acid 4% 24 hours 
PBS 30 minutes at 4°C 
Peracetic acid 0.1 % 3 hours at RT 
PBS 48 hours 
Table 2. Protocol of thymus decellularization without the use of Triton X-100 
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The matrix obtained was evaluated performing Haematoxylin and 
Eosin (H&E) staining and SEM analysis. 
 
  
Fig.33 H&E staining of decellularized thymus without the use of the Triton X-100 at 10X and 20X of magnification 
 
 
Fig.34 SEM analysis of the matrix obtained without the use of the Triton X-100  at two different magnification 
 
In the following is described table the second modified protocol 
tested on the mouse thymus to evaluate the action of the Triton X-100 on 
the ECM. 
 
Freze and thaw  
Trypsin 0.05% 30 minutes at 37°C 
Triton X-100 3% 48 hours 
PBS 30 minutes at 4°C 
Peracetic acid 0.1 % 3 hours at RT 
PBS 48 hours 
Table 3. Protocol of thymus decellularization without the use of Deoxycholic Acid 
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Fig.35 H&E staining of decellularized thymus without the use of the Deoxycholic acid  at 10X and 20X of magnification 
 
 
Fig.36 SEM analysis of the matrix obtained without the use of the Deoxycholic acid at two different magnification 
 
In the following table is described the third modified protocol tested 
on the mouse thymus to evaluate the action of the Deoxycholic acid on 
the ECM. 
 
Freze and thaw  
Triton X-100 3% 48 hours 
Deoxycholic acid 4% 24 hours 
PBS 30 minutes at 4°C 
Peracetic acid 0.1 % 3 hours at RT 
PBS 48 hours 
Table 4. Protocol of thymus decellularization without the use of Trypsin 
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Fig.37 H&E staining of decellularized thymus without the use of the Trypsin at 20X of magnification 
 
 
Fig.38 SEM analysis of the matrix obtained without the use of the Trypsin at two different magnification 
 
Freze and thaw  
Trypsin 0.01% 30 minutes at 37°C 
Triton X-100 3% 48 hours 
Deoxycholic acid 4% 24 hours 
PBS 30 minutes at 4°C 
Peracetic acid 0.1 % 3 hours at RT 
PBS 48 hours 
Table 5. Protocol of thymus decellularization with Trypsin diluited at 0,01% 
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Fig.39 H&E staining of decellularized thymus with the use of the Trypsin 0,01% at 10X and 20X of magnification 
 
 
Fig.40 SEM analysis of the matrix obtained with the use of the Trypsin 0,01%  at two different magnification 
 
FIG.41 DNA quantification of decellularized thymi in absolute value. 
 
Although the different solutions analyzed proved to be adequate to 
efficiently decellularize the thymic matrix, nevertheless they resulted too 
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aggressive for maintainance of its 3D structure, and basic ECM 
components. In addition, using H&E a violet staining meaning was 
sometimes detected, indicating presence of cellular debrids and nucleic 
acids, able to bind to the hematoxylin. In particular, trypsin either at 0,05% 
or 0,01% was able to destroy both the cells and ECM, as a consequence 
of the low protein amount present in the mouse thymus.  In addition, 
Triton X-100 and Deoxycolic acid resulted inadequate to efficiently clean 
the ECM from cell fragments and DNA contamination, although delicate 
enough to reasonable preserve the native structure of the thymus matrix.  
I, therefore, proceeded to modify the original protocol by adding 
MilliQ water and DNAse, based on protocols previously established with 
other organ like trachea [131], with the aim of preserving the ECM 
structure and, at the same time to improve its cleaning from contaminating 
cellular residues. 
MilliQ water was chosen for its ability to induce an osmotic stress to 
cells, and to eliminate them as floating fragments, as a result of the 
shaker movements forcing cellular membranes to pass from the organ 
into the solution. 
DNase was chosen for its ability to degradate DNA. It was used at 
the end of the decellularization process, to digest the DNA remained into 
the matrix without damaging the ECM. 
The new protocols tested are listed in the table below. 
 
 
 
 
    
 
 
102
 
 Protocol 
A 
Protocol 
B  
Protocol 
C 
Protocol  
D 
MilliQ water 72 
hours at 4°C 
√ √ √ √ x 2 cycles 
Triton X-100 3% 
12 hours at RT 
√ √   
Deoxycholic acid 
4% at RT 
 √  
24 hours 
√  
4 hours 
√ 4 hours x 
2 cycles 
DNAse 3hours at 
RT 
√ √ √ √ x 2 cycles 
Table 5. Scheme of different protocols used fot thymus decellularization 
 
An Haematoxylin and Eosin (H&E) staining and SEM analysis were 
performed to analyse resulting scaffold tissues obtained. They are 
showed in pictures below. 
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Fig.42 H&E staining of decellularized thymus with the protocol A  at 10X and 20X of magnification 
 
 
Fig.42 SEM analysis of the matrix obtained with the protocol A  at two different magnification 
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Fig.43 H&E staining of decellularized thymus with the use of the protocol D  at 10X and 20X of magnification 
 
 
Fig.44 SEM analysis of surface and the inner part of the matrix obtained with the use of the protocol B  at two different 
magnification.  
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Fig.45 H&E staining of decellularized thymus with the use of the protocol C at 10X and 20X of magnification 
 
 
Fig.46 SEM analysis of the surface and the inner part of the matrix obtained with the protocol C at two different 
magnification 
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Fig.47 H&E staining of decellularized thymus with the the protocol D  at 10X and 20X of magnification 
 
 
Fig.48 SEM analysis of the surface and the inner part of the matrix obtained with the protocol D  at two different 
magnification. 
 
A DNA quantification was performed to evaluate the remaining 
cellular material in resulting scaffolds obtained. 
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FIG.49 DNA quantification of matrices obtained in absolute value 
 
 
An immunoistochemistry for the mainly ECM components of the 
mouse thymus, collagen IV, fibronectin and laminin, was performed to 
evaluate changes in ECM proteins after the different protocols used. The 
native mouse thymus was used like positive control. 
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FIG.50 Immunohistochemical staining for collagen IV in native and decellularized thymi. A) native thymus; B) scaffold 
tissue obtained with the protocol A; C) scaffold tissue obtained with the protocol B; D) scaffold tissue obtained with the protocol C; 
E) scaffold tissue obtained with the protocol D. 
A 
D 
B 
C 
E 
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FIG.51 Immunohistochemical staining for fibronectin in native and decellularized thymi. A) native thymus; B) scaffold 
tissue obtained with the protocol A; C) scaffold tissue obtained with the protocol B; D) scaffold tissue obtained with the protocol C; 
E) scaffold tissue obtained with the protocol D. 
 
A 
D 
B 
C 
E 
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FIG.52 Immunohistochemical staining laminin in native and decellularized thymi. A) native thymus; B) scaffold tissue 
obtained with the protocol A; C) scaffold tissue obtained with the protocol B; D) scaffold tissue obtained with the protocol C; E) 
scaffold tissue obtained with the protocol D. 
 
Using these new protocols, a better cleaning and maintainance of 
the 3D structure of the thymic ECM mouse was achieved. 
In particular, using the protocol A, based on Triton X-100, milliQ 
water and DNAse, I observed only a modest decrease in the quantity of 
cellular contamination, whereas the 3D structure of the matrix was 
maintained quite well. This was also confirmed by the 
immunohistochemical analysis, that showed presence of laminin, 
A 
D 
B 
C 
E 
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collagen IV and fibronectin in distribution consistent with that of the 
native control tissue.  
In contrast, using protocol B based on addition of Deoxycholic Acid, 
the quantity of DNA decreased in a significant manner, while no changes 
occurred to the 3D matrix structure.  Specifically, using both H&E staining 
at light microscopic level, and SEM I noticed that the 3D structure of the 
thymic matrix was reasonably preserved, although some holes formed, 
possibly due to the removal of resident cells. In addition, ECM proteins 
were observed by immunocytochemistry in a pattern resembling that of 
protocol A, but clustered as a result of the absence in resident cells.  
Collectively, these results suggested that protocol B could provide a good 
scaffold system for homing and proliferation of seeded TEC. 
Using protocol C, in which the Deoxycholic Acid was applied only for 
4 hours, no changes in the 3D matrix structure were observed.  However, 
an improvement in the size of the pores occurred, suggesting that the 
Deoxycholic Acid was able to efficiently remove cells even if used for a 
short time.  In addition, the amount of DNA decreased to a reasonable 
extent, suggesting a primary decellularizing role for the Deoxycholic Acid.  
Finally, no relevant changes were found in the amount of ECM proteins. 
At variance with previous protocols, using protocol D I found 
differences in DNA quantity, matrix size, and ECM components.  
Specifically, the amount of DNA was increased compared to protocol C, a 
reduction in matrix size occurred, likely depending on the osmotic action 
of MilliQ water, and the long time of shaking as well, whereas a reduction 
in fibronectin staining was equally apparent.  
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In summary, the best protocols proved to be B and C, able to 
guarantee a very little amount of contaminating DNA, while maintaining 
the native 3D matrix structure, and protein compositions of the ECM. 
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4.2 ROLE OF DECELLULARIZED THYMIC MATRICES 
IN REGULATING THE IN VITRO BEHAVIOUR OF TEC 
 
The decellularized, 3D thymic matrices obtained using the 
previously described protocol were used as natural, 3D scaffold to study 
the behaviour of seeded TECs. 
Decellularized matrices could influence TEC by releasing different 
factors into the culture medium, by directing them to their 3D structure 
or by influencing them through the ECM composition. 
Specifically, I started to evaluate the role played by decellularized 
matrices prepared with the protocol C, which seemed to have the best 
amount of ECM proteins and low quantity of DNA. To this purpose 
these matrices were transformed in a sort of “sponge”, as detailed in 
Material and Methods, and their structure analysed to define the 
acquired, final geometry. SEM analyses were performed on scaffold 
obtained and the shape of its surface and their inner parts are showed 
in figures below. 
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Fig.53 SEM analysis of the surface of the matrix obtained with the protocol C  at two different magnification. 
 
 
Fig.54 SEM analysis of the inner part of the matrix obtained with the protocol C  at two different magnification. 
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Sem analyses revealed that these “3D scaffolds” had pores big 
enough, and with a regular distribution to ensure homing and possibly 
proliferation of eventually seeded TEC.  
I, therefore, decided to verify whether the 3D scaffolds made with 
decellularized matrix might release soluble factors in the culture media 
able to influence the growth and the differentiation of seeded TECs. 
To this aim, scaffolds were used to condition the culture media for 
48 hours at 37°C. Media, then were diluited at 5% and filtered throught 
a filter of 0,2µm to select the soluble factors released getting rid of 
anymatrix debris. 
At the same time, TECs were seeded on standard 48-well plates, 
at a density of 50.000 cells/well and conditioned medium was added 24 
hours later the seeding, to allow attachment of seeded elements to the 
bottom of the plastic plate. Subsequently the medium change was done 
every 48 hours. 
Cells were followed day by day taking pictures of them at every 
medium change having like positive control cells cultured with fresh 
media. 
Pictures, taken every medium change for the positive control, are 
showed below. 
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Fig.55 Pictures taken with the light microscope in the control conditon during all the culture at every medium change. 
 
Pictures, taken every medium change for cells cultured with 
medium conditioned at 5%, are showed in the figure below. 
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Fig.56 Pictures taken with the light microscope during all the culture, at every medium change, for the cells cultured with 
medium conditioned with scaffold obtained after disruption, at 5% diluition. 
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Fig.57 Pictures taken with the light microscope during all the culture, at every medium change, for the cells cultured with 
medium conditioned by decellularized matrix at 5% diluition. 
 
Following initial seeding of culture cells in all conditions, I found 
that in the first days they were few, due to the death of differentiated  
cells, but from day 5 cells started to proliferate reaching confluence and 
cell clusters at day 9.  
Their vitality and markers expression was confirmed by FACS 
analysis performed at day 12, underlying an expression of MHC II by 
TEC. FACS data are showed below for the positive control and for 
different culture conditions. 
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Fig.58 Cell surface marker characterization of the 2D positive control of TEC as determined by flow cytometric analysis. 
TEC were analyzed for: A) size; B) DAPI staining for the vitality; C) elimination of doublets; D) EpCam staining; E) MHC II 
staining. 
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Fig.59 Cell surface marker characterization of TEC, cultured with medium conditioned with scaffold obtained after 
disruption of decellualrized tissue, as determined by flow cytometric analysis. TEC were analyzed for: A) size; B) DAPI staining for 
the vitality; C) elimination of doublets; D) EpCam staining; E) MHC II staining. 
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Fig.60 Cell surface marker characterization of TEC, cultured with medium conditioned with decellualrized tissue, as 
determined by flow cytometric analysis. TEC were analyzed for: A) size; B) DAPI staining for the vitality; C) elimination of 
doublets; D) EpCam staining; E) MHC II staining. 
 
In comparing cell shape, cell number and TECs marker expression, I 
found that only MHC II antigens resulted slighly higher in the cells  treated 
with the conditioned medium compared to controls, suggesting a 
favourable effect of matrix products on TECs differentiation state. 
In a following step,these culture conditions were applied to cells 
cultured in fibrin gel. This with the aim to determine whether the changes 
in the above mentioned parameters could be detected also in cells grown 
in a 3D environment, known to induce MHC II expression as in vivo 
conditions.  
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FACS data are showed below for two different positive controls in 
two different configuration (2D and 3D) and for different culture conditions. 
 
 
Fig.61 Cell surface marker characterization of 2D positive control of TEC as determined by flow cytometric analysis. 
TEC were analyzed for: A) size; B) DAPI staining for the vitality; C) elimination of doublets; D) EpCam staining; E) MHC II 
staining. 
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Fig. 62 Cell surface marker characterization of TEC, cultured in 3D fibrin gel, as determined by flow cytometric analysis. 
TEC were analyzed for: A) size; B) DAPI staining for the vitality; C) elimination of doublets; D) EpCam staining; E) MHC II 
staining. 
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Fig.63 Cell surface marker characterization of TEC, cultured in 3D fibrin gel with medium conditioned with scaffold 
obtained after disruption of decellualrized tissue, as determined by flow cytometric analysis. TEC were analyzed for: A) size; B) 
DAPI staining for the vitality; C) elimination of doublets; D) EpCam staining; E) MHC II staining. 
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Fig.64 Cell surface marker characterization of TEC, cultured in 3D fibrin gel with medium conditioned with decellualrized 
tissue, as determined by flow cytometric analysis. TEC were analyzed for: A) size; B) DAPI staining for the vitality; C) elimination 
of doublets; D) EpCam staining; E) MHC II staining. 
 
In preliminary studies still in progress, after 12 days in 3D fibrin culture 
and conditioned medium, seeded TECs depicted increased expression of 
MHC II antigens, suggesting a direct stimulatory role of the scaffold products 
on differentiation parameters for TECs.  
 Similarly, preliminary studies have also been conducted to assess the 
role of TEC seeding directly on the decellularized matrix, but limited trapping 
of the cell suspension by the matrix requires further studies. However, cell 
viability assays, based on MTT, proved that, at day 3 of culture cells were 
able to attach and proliferate on the decellularized matrix (fig 65), and that 
they survived and proliferate up to 10 days in static culture (figure 66).   
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Fig.65 Pictures of the MTT assay after 3 days of culture. The first one taken through the steromicroscope and the other 
one with a normal photocamera. Cells alive, that metabolize the MTT, are stained in violet. 
 
 
 
Fig.65 Pictures of the MTT assay after 10 days of culture. The first one taken through the steromicroscope and the 
other one with a normal photocamera. Cells alive, that metabolize the MTT, are stained in violet. 
 
 
These results are very encouraging, suggesting that TECs seeded on 
native, decellularized matrixes are metabolically active and, likely 
favourably respond to the 3D geometry of the substrate by preserving 
their proliferation potential.   
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5. CONCLUSIONS AND FUTURE PERSPECTIVES 
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During my PhD tenure at the Tissue Engineering Laboratory of the 
University of Basel I have investigated the possibility to obtain an efficient 
protocol for the decellularization of the mouse thymus, and to use it as a 
scaffold for culturing Thymic Ephitelial Cells. Since TEC in normal 2D 
condition on plastic loose their differentiation state, I investigated a suitable 
3D alternative, in particular a 3D scaffold able to support their growth, and 
maintain their differentiation state. 
  Due to its anatomy, the thymus is a very difficult organ to 
decellularize. Indeed, it is served only by small vessels, that cannot be 
easily used to perform a perfusion-decellularization process. For this 
reason, I developed an original decellularization process by immersion.  
Two different protocols satisfied the main characteristics of a decellularized 
matrix, according to qualitative and quantitative assays. In particular, the 
quantity of DNA was less than 10% in absolute value, no positive staining 
for cells was found after the decellularization, and the 3D structure and 
composition of the ECM were maintained.   In addition, I was able to prove 
that the decellularized matrixes were not cytotoxic for the cells, and were 
able to increase expression of MHC II antigens with respect to control cells 
grown in standard conditions. 
  Further analysis are required to study whether and to which gene 
level these effects take place, which soluble factors are released by the 
decellularized matrix in the culture media, and their possible effects on the 
differentiation state of TECs. 
  Improvements will be done in seeding efficiency of the cells directly 
on the matrix, possibly also exploiting appropriate bioreactor conditions, 
and in the choice of appropriate markers showing the level of differentiation 
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reached by the seeded TECs. 
After a complete characterization of the culture system, these 
innovative natural scaffolds could be used to improve the standard culture 
conditions of TEC, to study in vitro the action of different factors on their 
differentiation genes, and to test the ability of TECs to induce in vitro 
maturation of seeded T lymphocytes.   
In a near future, I also envisage the use of a completely 
recellularized, thymic matrix as a tool to test in vivo lymphocyte maturation 
after its implant under the kidney capsule of the athymic mice, and possibly 
as an innovative therapeutic tool to rescue conditions of immunodepression 
in specific animal models of immunodeficiency. 
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